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ABSTRACT 
 
Vaccines against infectious diseases are a corner stone of public health globally. 
Vaccine technology based on attenuation, conventionally “killed” or cellular sub-units 
suffer from significant drawbacks. Live attenuated vaccines impart strong cellular and 
humoral immune response compared to inactivated or subunit vaccines, but there is an 
increased risk of infection from the potential virulence reversion in such formulations. 
The current study explores the use of eBeam irradiation as a novel tool for vaccine 
generation. The value of eBeam based vaccines is that, they combine the safety of 
“killed” vaccines, yet retain the immunogenicity of “attenuated” vaccines. The principle 
of eBeam vaccine is eBeam irradiation will only irreversibly damage the target 
microorganism’s nucleic acid without modifying the antigenic properties of surface 
macromolecules.  In this study microbiological characterization of eBeam based S. 
Typhimurium (EBST) vaccine was carried out. The immunological correlates of 
protection induced by the EBST in dendritic cell (DC) (in vitro) and mice (in vivo) 
model were also assessed.  
Results showed that eBeam inactivation preserved the potent proinflammatory 
and immunogenic properties of S. Typhimurium. The EBST remained metabolically 
active yet unable to multiply under favorable in vitro and in vivo conditions. The EBST 
potently stimulated innate pro inflammatory response (TNFα) and maturation (MHC-II, 
CD40, CD80 and CD86) of DC. Immunostimulatory potential of EBST was on par with 
live Salmonella, and most importantly on par with a commercial Salmonella vaccine.  
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Results from the mice challenge studies demonstrated the involvement of CD4+T cells as 
key player in cell mediated immune response of EBST immunized mice, triggering the 
production of Th1 cytokine IFNγ. This indicates the stimulation and development of 
robust Salmonella specific T cell response similar to that caused by the live attenuated 
vaccine (AroA- ST) formulation. The colonization of virulent Salmonella was also 
reduced in EBST immunized mice similar to AroA immuninized mice. The EBST 
retained stable immunogenic properties for several months at room temperature, 4°C, -
20°C and also after lyophilization. These findings highlight the potential of eBeam 
technology as an effective and affordable next generation vaccine platform to address 
global public health issues. 
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NOMENCLATURE 
 
ST Salmonella Typhimurium 
EBST Electron beam irradiated Salmonella Typhimurium 
HKST Heat killed Salmonella Typhimurium 
CFU Colony Forming Units 
PBS Phosphate Buffered Saline 
DC Dendritic cell 
BMDC Bone marrow derived dendritic cell 
CD4 Cluster of differentiation 4 
CD8 Cluster of differentiation 8  
IFNγ Interferon gamma  
TNF/TNFα Tumor necrosis factor  
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CHAPTER I 
INTRODUCTION 
 
The National Center for Electron Beam Research (NCEBR) at Texas A&M 
University has been at the forefront of developing different applications for high energy 
electron beam (eBeam) irradiation technology. These include applications in the 
development of high value pharmaceuticals, food safety, food security, phytosanitary 
applications, polymer modifications and wastewater treatment technologies.  The 
Center’s guiding principles are to exploit this technology across different disciplines so 
as to “clean, heal, feed, and shape this world and beyond”. Over the past few years, the 
Center in collaboration with the USDA-ARS in College Station has demonstrated that 
eBeam irradiation can be used to develop immuno-modulators that can have commercial 
value as vaccines (Jesudhasan et al., 2010; Kogut et al., 2012).  
The basis of eBeam vaccines is that eBeam (i.e., ionizing) radiation will only 
destroy the target microorganism’s nucleic acid, without affecting any of the surface 
macromolecules. Ionizing radiation inactivates microorganisms by directly causing 
breaks in DNA strands, or indirectly by the generation of radiolytic byproducts that 
interact with DNA causing DNA breakages. The eBeam irradiation has been used for 
decades for microbial inactivation for sterilization and pasteurization (Dziedzic-
Goclawska et al., 2005; Poon et al., 2004; Rivera et al., 2011 and Cabeza et al., 2010).  
The eBeam irradiation at appropriate doses can be used to inactivate large volumes of 
microbial cultures or sterilize materials (Pillai et al., 2007; Sommers and Fan, 2006 and 
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Brahmakshatriya et al., 2009). There are a number of salient advantages of eBeam based 
vaccines including its suitability for vaccine formulations that are either in a liquid, 
lyophilized, or semi-solid state (Pillai et al., 2007). Also, importantly, the technology to 
accurately deliver and measure varying eBeam energies and doses provides the added 
possibility of being able to customize this technology for scaling up vaccine production 
processes.  
In order to understand the immune response mechanisms triggered by eBeam 
irradiated vaccines, Salmonella was chosen as the model vaccine. Salmonella enterica 
serovars consists of group of gram negative facultative intracellular bacteria that causes 
a variety of infections ranging from acute gastroenteritis to systemic enteric fever, and is 
regarded as a leading cause of food borne infections in humans as well as livestock 
(CDC, 2009; Mittrucker et al., 2000). Among the serovars of Salmonella enterica, S. 
Typhimurium (ST) gives rise to systemic infection and gastroenteritis in different animal 
models (Eisenstein, 1999), hence accepted as an experimental model for more virulent 
Salmonella serovars. Immune response of S. Typhimurium is widely studied in mice 
model (Mittrucker et al., 2000), hence would serve as an ideal candidate to understand 
immune mechanisms induced by eBeam irradiated vaccine preparations.  Preliminary 
studies conducted in laying hens, support the ability of irradiated vaccine to reduce 
bacterial colonization during challenge studies and provided evidence of the stimulation 
of the immune response (Jesudhasan et al., 2010).  
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Several attenuated strains of Salmonella are currently being considered as live 
vaccine candidates as they are capable of inducing humoral as well as cellular immune 
responses (Mittrucker et al., 2000). Studies have revealed that live vaccines are more 
effective than killed or non-replicating vaccines especially against pathogens that require 
cell mediated defenses like Salmonella (Thatte et al., 1993; Harrison et al., 1997). But, 
safety concerns limit the utilization of live/attenuated preparations as vaccine (Datta et 
al., 2006), especially considering the increasing number of chronically 
immunocompromised individuals, with a high risk of contracting vaccine induced 
diseases after immunization (McFarland, 1999, Wolfe and Bhat, 2005). In this context, 
eBeam irradiated vaccine serves as an ideal alternative to live attenuated vaccine 
provided, they are capable of inducing the cellular and humoral immune response similar 
to or better than that by the live vaccine preparations.  
 The long term goal of this research is to use high energy electron beam (eBeam) 
technology to develop effective, low-cost irradiated vaccines, which can impart long 
term immunity against pathogens. The central hypothesis is that high energy electron 
beam (eBeam) irradiation can inactivate Salmonella, but would preserve the 
immunomodulatory properties enabling it to serve as an efficacious vaccine. In this 
study, we conducted detailed microbiological characterization of eBeam based 
S.Typhimurium (EBST) vaccine and assessed the immunological correlates of protection 
induced by the EBST using in vitro and in vivo assays. Dendritic cell lines (DC) and 
mice studies were used for in vitro and in vivo assays respectively. These studies were 
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performed to gain a deeper understanding and develop new knowledge about the 
mechanisms by which eBeam vaccines confer immunity.  
 The specific objectives of the research were: 
(1) To develop eBeam irradiated ST that has effective immune-modulation potential. 
(2) To perform microbiological characterization of the eBeam inactivated vaccine to 
determine the stability and longevity of vaccine.  
(3) Evaluate the immunogenicity of eBeam irradiated vaccine and understand the 
underlying immune response mechanism triggered by the vaccine. 
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CHAPTER II 
LITERATURE REVIEW 
 
Vaccines- background 
Vaccines are considered as a revolutionary advancement in the history of human 
and animal health care.  Ever since the use of first cowpox virus vaccine by Edward 
Jenner in 1796, vaccination has played a major role in the conquest of infectious diseases 
and in improving public health. One of the greatest benefits of vaccination to the modern 
society is the increase in life expectancy. Increased life expectancy is due to the greater 
control of infectious diseases, decreased early mortality and decreased exposure to acute 
and chronic inflammatory processes (Rappuoli et al., 2011; Wilson and Marcuse, 2001). 
Key contributions of vaccination include small pox eradication, almost complete 
elimination of poliomyelitis, reduction in incidence of diphtheria, pertussis, tetanus, 
measles, mumps, rubella, hepatitis A, hepatitis B, Haemophilus influenzae type b, 
pneumococcus etc. (Rappuoli et al., 2011).  
 There are several criteria for an effective vaccine (Adapted from Janeway et al., 
2001) 
 Vaccines must be safe - When administered, the vaccine itself must not cause 
illness or death. 
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 Vaccines should be protective - Vaccines must protect the host against 
subsequent re-exposure to pathogen. 
 Vaccine should provide sustained protection - The protection imparted by 
vaccine should be long lasting. 
 Induction of neutralizing antibodies - Vaccines that develop neutralizing 
antibodies prevent infection of cell, which is particularly useful in case of 
vaccines like polio vaccine where the virus infects irreplaceable cells such as 
neurons. 
 Induction of protective T cells - Development of cell mediated immune responses 
is effective especially for control of intracellular pathogens. 
 Vaccines should have practical value - This includes cost-effective production, 
and biological stablity. Vaccines should also be easy to administer with 
negligible to low side effects. 
Effectors of vaccine response 
In order to control or eliminate diseases, vaccines must mediate long term 
protective immunity. Long term immunity is conferred by antigen specific immune 
effectors and by the induction of immune memory cells that are capable of rapid 
reactivation upon re-exposure to pathogen (Siegrist, 2008). Major vaccine immune 
effectors include antibodies, cytotoxic CD8+ T lymphocytes (CTL) and CD4+ T helper 
lymphocytes (Th). Antibodies produced by B lymphocytes in response to antigen 
stimulation, are capable of neutralizing or binding to specific pathogens or toxins. 
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Cytotoxic T cells recognize and lyse the infected cells directly or secrete specific 
antiviral cytokines. Helper T cells provide adequate growth factors and signals for 
generation and maintenance of both B cells and CTL. The CD4+ helper T cells are 
divided into Th1 and Th2 subtypes. Upon activation, Th1 cells differentiate into cells 
mainly secreting Th1 cytokines such as IFNγ, TNFα, IL-2 that exert antimicrobial 
functions by supporting cytotoxic T cells and macrophages. On the other hand, activated 
Th2 cell differentiate into cells secreting IL-4, IL-6, IL-10 providing support essentially 
to B lymphocytes. Immune memory T cells are also considered important determinants 
of vaccine efficiency. Memory T cells are divided in to effector memory cells (Tem) and 
central memory cells (Tcm) based on their phenotype and function. Effector memory T 
cells traffic through non lymphoid organs monitoring specific microbial peptides. They 
act immediately upon pathogen recognition and have high cytotoxic potential. Central 
memory T cells, on the other hand, traffic through lymph nodes, bone marrow and 
recognize antigens transported by activated dendritic cells. Their action is delayed but 
exhibits high proliferative potential and limited cytotoxic capacity (Siegrist, 2008; 
Sallusto et al., 2004). 
Classification of vaccines 
For a long time, , empirical approaches such as use of live attenuated or killed 
organisms and partially purified components of organisms were used for developing 
vaccines (Plotkin, 2003). Broadly, vaccines can be classified into live attenuated and 
inactivated vaccines (CDC, 2012).  
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Live attenuated vaccines are derived by modifying wild type or natural disease 
causing pathogen. The pathogen is “attenuated” or “weakened” by different methods 
which reduces its ability to cause disease, but retains the ability to replicate and produce 
immune response (CDC, 2012). There are different approaches used for generating live 
attenuated vaccines. One such approach pioneered by Edward Jenner is to use a natural 
pathogen in another host to serve as a vaccine in a different host system. As a result, 
there occurs an abortive infection in the recipient host which triggers immune response. 
This approach was used in case of cowpox vaccine, parainfluenza vaccines etc. (Plotkin, 
2003). Attenuation of pathogens can also be achieved by extensively passaging them in 
an in vitro tissue culture model or an animal host till there reaches a balance between the 
loss of virulence and retention of immunogenicity. The BCG, oral polio vaccine, flu, 
measles and yellow fever vaccines were developed using this approach (CDC, 2012; 
Plotkin and Plotkin, 2013). Use of a naturally occurring attenuated strain of pathogen is 
also possible, such as the use of Type 2 polio virus (Arnon, 2011). The most common 
method of attenuation is to select mutants that are generated by cold adaptation (rubella, 
live flu), temperature sensitivity (respiratory syncytial virus), auxotrophy (Ty21a typhoid 
vaccine) (CDC, 2012; Plotkin, 2003; Rappouli et al., 2011).  
Live attenuated vaccines replicate like the original pathogenic strains and 
therefore cause immune responses similar to a natural infection. Thus they confer 
effective long term immunity to host. They are required in only lower doses and works 
effectively with different routes of vaccine administration (Siegrist, 2008). But, live 
attenuated vaccines can cause severe reactions in case of immunocompromised 
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individuals making it unsafe for administration. The reversion of attenuated organisms to 
pathogenic form has been reported in case of poliomyelitis referred as vaccine associated 
paralytic poliomyelitis (VAPP) (Wilson and Marcuse, 2001). The immune response of 
live attenuated vaccines can be affected by interfering circulatory antibodies present in 
the host system, which prevents replication of attenuated vaccine. As a result, such live 
vaccines can mount only a poor immune response and thus causes vaccine failure. Live 
attenuated measles vaccines are known to be very sensitive to circulating antibodies 
(CDC, 2012). Being live organisms makes the attenuated vaccines very fragile and prone 
to damage by heat or light. Hence, proper storage and handling is required for live 
attenuated vaccines (Plotkin and Plotkin, 2013).  
As the name suggests, inactivated vaccines are obtained by inactivating the 
whole disease causing organisms using physical methods such as heat or chemical 
methods such as formalin inactivation (Plotkin, 2003). For developing fractional 
inactivated vaccines, the organisms are further treated and different immunogenic 
components are purified. Such fractional inactivated vaccines include subunit as well as 
toxoid vaccines. Polysaccharide vaccines are also inactivated vaccines that contain 
polysaccharide molecules present in surface capsules of bacteria. Conjugate vaccines 
have also been produced by combining protein molecules with polysaccharide to 
develop vaccines with increased immunogenicity. Recombinant vaccines are developed 
using genetic engineering technology where gene segments from pathogenic organisms 
are inserted to nonpathogenic host. Table 2-1 provides the list of different vaccine 
classifications and examples of vaccines developed under each category.  
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Table 2-1. List of different vaccine classifications and examples of vaccines developed 
under each category 
 
Vaccine development 
strategy 
Examples 
Live attenuated vaccine   
Viral measles, mumps, rubella, vaccinia, varicella, zoster, yellow 
fever, rotavirus, intranasal influenza, oral polio 
Bacterial BCG, oral typhoid 
Inactivated vaccines   
Whole cell vaccines    
Viral polio, hepatitisA, rabies, influenza 
Bacterial pertussis, typhoid, cholera, plague 
Fractional vaccines   
Subunit hepatitis B, influenza, acellular pertussis, human 
papillomavirus, anthrax  
Toxoid diphtheria, tetanus 
Polysaccharide vaccine pneumococcus, meningococcus, Salmonella Typhi (Vi) 
Conjugate polysaccharide Heaemophilus influenzae typeb, pneumococcus, 
meningococcus 
Recombinant vaccine hepatitis B, human papillomavirus 
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Since inactivated vaccines are incapable of replication, they are considered safe 
even for immunocompromised individuals. Inactivated vaccines are also less affected by 
the circulating antibodies present in the host system. But, multiple doses of inactivated 
vaccines need to be administered to obtain immune response. In contrast to live 
vaccines, inactivated vaccines confer poor cell mediated immune response, hence are 
considered less immunogenic compared to live attenuated vaccines (Siegrist, 2008; 
Plotkin, 2003). Additional components such as adjuvants can be added to enhance the 
immunogenicity of inactivated vaccine. 
Components in vaccine 
Apart from the active component (antigen), vaccine formulations include various 
additional components that help in increasing, maintaining, and preserving 
immunogenicity of vaccine (Eldred et al., 2006). The components of vaccine include 
active component, adjuvant, diluent, stabilizer, preservatives and trace compounds. 
Antigens are the active components of the vaccine. These could be either live 
attenuated, inactivated or subunits of the antigen. Adjuvants are compounds that are used 
to increase the immune response of vaccine. Adjuvants can be divided into delivery 
systems or immunomodulators (Coffman et al., 2010). Delivery system adjuvants help in 
prolonging the antigen deposition at the site of injection, recruiting more dendritic cells 
(DC). Immunomodulators provide additional activation and differentiation signals to DC 
and monocytes (Siegrist, 2008). Commonly used adjuvants include aluminium salts, 
Freund’s adjuvant, oil –in- water emulsion, toll like receptor ligands. Even though 
12 
 
progress is being made in the use of adjuvants, none of the currently used adjuvants 
trigger the immune response to the same degree as that of live vaccines (Siegrist, 2008). 
Diluents are usually sterile liquids such as water or saline that is provided with 
the vaccine for diluting the vaccine to appropriate concentration for administration. 
Stabilizers refer to the additives that help in maintaining effectiveness of vaccine by 
keeping the vaccine components stable. Commonly used stabilizers include lactose, 
sucrose, monosodium glutamate (MSG), glycine, bovine serum albumin, gelatin etc. 
(Eldred et al., 2006). Preservatives are added to vaccine formulations to prevent the 
fungal or bacterial contamination. A mercury containing compound, Thimerosal was 
used as a preservative. Use of these compounds are now highly restricted owing to the 
mercury content in the formulation. Preservatives are added mostly to multidose vials to 
prevent contamination. Trace compounds refers to the minute quantities of substances 
remaining from the production process of vaccine such as formalin traces from formalin 
inactivated vaccines, cell culture fluids, egg proteins, antibiotics etc. Sometimes 
antibiotics are also added to the formulation during the process of manufacturing to 
prevent bacterial contamination. Some of the commonly used antibiotics include 
neomycin, polymyxin B and gentamicin. It is always recommended to properly 
scrutinize for specific vaccine components before vaccine administration to avoid any 
potential allergic or adverse reactions. 
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Risks and public concerns associated with vaccination 
Recent years witnessed an increase in public concerns over the safety and net 
benefits of vaccines. This might be because, the fear of vaccine preventable disease 
waned among public and there is increased awareness about potential adverse effects of 
vaccines (Wilson and Marcuse, 2001). Vaccines are not completely free from any side 
effects or adverse effects, but most of them are mild, rare, or could be due to 
coincidence. As part of the evaluation of vaccine safety, researchers conduct assessment 
of any possible causal relationship of vaccination to any specific adverse effect (NRC, 
2012).  One of the major vaccine safety issues arose when vaccine induced poliomyelitis 
was reported around 1955. It was attributed to the insufficient inactivation of poliovirus 
in certain lots of inactivated polio vaccine (IPV) which resulted in almost 260 cases of 
vaccine induced polio (Wilson and Marcuse, 2001).  Another huge public outcry was 
reported when IPV was found contaminated with simian virus- 40 (SV-40), which is 
oncogenic in several species. The contamination occurred from the use of rhesus 
monkey kidney cells which were previously contaminated with SV-40. Sporadic cases of 
vaccine associated paralytic poliomyelitis (VAPP) from the oral administration of live 
attenuated polio vaccine (OPV) were also reported (Strebel et al., 1992). Another case of 
vaccine recall was reported in case of a new generation live recombinant viral vaccine, 
Rhesus-human reassortment rotavirus vaccine. Almost 13 cases of serious intestinal 
obstructive disorder (intestinal intussusception) was reported in vaccinated children 
which led to suspension of vaccine in 1999, one year after its licensing (Chang et al., 
2001). Several physical conditions and diseases have been reported to be associated with  
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Table 2-2. List of new strategies for vaccine development (Adapted from Rappouli et al., 
2011) 
 
Vaccine development strategy Examples 
Cell culture Rabies, Japanese encephalitis virus, varicella zoster, 
hepatitis A, rotavirus, Avian influenza, H1N1 
influenza, small pox, yellow fever virus 
Recombinant DNA, virus- like 
particles 
Hepatitis B, acellular pertussis, lyme disease, HPV 
Reverse vaccinology meningococcus B, Staphylococcus aureus 
Conjugation H. influenzae type b (Hib), meningococcus, 
pneumococcus, GroupB Streptococcus, typhoid 
Combination Diphtheria-pertussis-teteanus-Hib, Hib- hepatitis B, 
DTaP-Hib, hepatitisB-hepatitis A, diphtheria- 
tetatnus-acellular pertussis-poliovirus-hepatitis B 
New adjuvants Influenza, HPV, H1N1 influenza, vaccines from 
superior alum formulation, TLR agonists 
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certain vaccines in recent years, which have no sound epidemiological evidence to 
support the association. Few of such hypothetical associations include autism due to 
MMR vaccine (Wakefield et al., 1998) and use of thimerosal in the vaccine (Ball et al., 
2001), multiple sclerosis associated with hepatitis B vaccine (Ascherio et al., 2001), 
allergy due to adjuvant alum (Kristensen et al., 2000; Wilson and Marcuse, 2001). To 
address such risks and public concerns, it is highly important to develop effective and 
safer vaccine particularly for diseases of global importance. Stringent vaccine safety and 
efficacy trials should be conducted pre and post licensing of vaccines. There is an ever 
increasing demand for newer approaches in developing safer and effective vaccines to 
address the public concerns. 
New approaches in vaccine development 
Recent years have witnessed a greater interest for next generation vaccine 
development technologies. Some of the revolutionary technologies include use of 
recombinant DNA technology for  development of hepatitis B vaccine, conjugation 
technology for Haemophilus influenzae type b vaccine, reverse vaccinology for 
meningococcus B vaccine, virus like particles (VPL)  against human papilloma virus and 
the relatively new nucleic acids and synthetic vaccine technology (Plotkin, 2003; 
Rappuoli et al., 2011). Table 2-2 provides a brief list of some of the new and improved 
strategies used for vaccine development (Rappouli et al., 2011). This review focusses on 
the approach involving the use of ionizing radiation for vaccine development, with 
emphasis on electron beam (eBeam) technology. 
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Electron beam radiation (eBeam) – background and terminologies 
There are majorly two sources of ionizing radiation- radioisotopes and linear 
accelerators. Both these sources produce short wave high energy radiation which have 
similar effects. Radioactive isotopes such as 137Cs and 60Co emit gamma radiation, 
whereas, electron beam is machine generated (linear accelerator), which does not 
involve any radioactive sources. The eBeam uses near-speed-of-light electrons generated 
from electricity as ionizing radiation source (Tahergorabi et al., 2012). In eBeam, 
electrons are accelerated under controlled electric and magnetic fields in a single 
direction to penetrate the target. Many public acceptance studies on ionizing radiation 
products showed that consumers preferred machine generated eBeam compared to radio 
isotope derived gamma radiation (Mitchell, 1994; Gehringer, 2003). The effect caused 
by eBeam depends upon certain key factors such as dose, dose distribution, stopping 
power, range and penetration of the eBeam.  
When electrons travel through a target material, they tend to lose energy due to 
excitation and ionization of atoms present within the material. This average linear rate of 
energy loss of these electrons in a particular medium is referred to as “stopping power”. 
Stopping power is generally expressed in terms of MeV per cm. It is also referred to as 
the linear energy transfer (LET) of the particle with units generally expressed as keV per 
μm (Turner, 1995). Stopping power and LET are closely related to the dose imparted to 
the material by the electrons traveling through that material. Dose refers to the energy 
deposition per electron colliding with an atom in the target surface thereby generating 
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secondary, tertiary electrons to dissipate off the energy. Absorbed dose is defined as the 
quantity of the ionizing radiation energy which is imparted per unit mass of the specified 
material being irradiated (Sommers and Fan, 2006). The SI unit of absorbed dose is the 
gray (Gy). Conveniently expressed as kilogray (kGy). One Gy represents one joule of 
energy deposited per kilogram of material. One kilogray refers to 1000 Grays.  
Depth dose distribution profile depicts the energy absorbed by a unit mass at 
particular depth. This dose- depth distribution curve consists of energy absorbed from 
the incident electron or the absorbed dose as the ordinate and the depth of penetration as 
the abscissa. The dose distribution profile over different depths varies based upon the 
source of electron. Since the electron distribution is not constant, certain positions in the 
target material receives more energy compared to other positions. The uniformity of 
electron deposition is thus represented by a Dmax/Dmin ratio, where Dmax and Dmin 
correspond to depths receiving maximum and minimum dose respectively. 
  The electron distribution pattern is markedly different in case of single and 
double sided eBeam. In case of a double sided dose distribution curve energy deposition 
occurs from both the sides of the target material. Hence the range of the particle can be 
increased by using a dual e-beam which allows for the electrons to travel more distance 
inside the target material before it comes to rest (Turner, 1995). The dual beams overlap 
and would result in a synergistic effect at the point of convergence which maintains the 
dose distribution uniform throughout the thickness of the material.   
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Microbial inactivation by electron beam radiation 
When microbial cells are exposed to ionizing radiations as in case of electron 
beam, it causes several direct as well as indirect effects that results in microbial 
inactivation. The primary effects of the eBeam is due to the collision of electrons in the 
microbial cell which results in breakdown  of the vital cellular components such as 
nucleic acid whereas the secondary effects are due to the production of radiolytic species 
causing indirect damage to the cell.  
The primary target of ionizing radiation is the genetic material of cell as they 
form the major component of the cell (Urbain et al., 1996). Damage to proteins, lipids 
and RNA contributes only to a lesser extent to microbial lethality (Sonntag, 1987). Upon 
entering the cell, eBeam induces nonspecific collision of electrons with atoms of the 
microbial cell that causes single and double stranded breaks in microbial DNA resulting 
in disintegration of DNA double helix (Tahergorabi et al., 2012; Smith and Pillai, 2004). 
Disintegration of DNA affects the cell division, resulting in cellular reproductive death 
of microbe (Tahergorabi et al., 2012). The damage is directly proportional to the genome 
size and has an inverse relationship with the radiation dose (Alsharafi and Mullbacher 
2009). Microbial cell is capable of single strand as well as most of the double stranded 
(not directly opposed) DNA repair with the help of the DNA polymerase enzyme owing 
to its proof reading activity. Directly opposed double stranded DNA repair is hard to 
undertake as there does not exist a corresponding complementary base to provide the 
correct nucleotide information to repair the strand breakage. This kind of DNA strand 
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damage could possibly accumulate together to bring about lethal mutations in the nucleic 
acid of the microbial cell (Bartek and Lukas, 2003). 
Apart from the DNA damage there also occurs production of a range of radiolytic 
species as a result of the series of oxidation reduction reactions occurring in the course 
of electron transfer from one atom to another. Water constitutes a major portion of the 
microbial cell and hence would suffer from the radiolytic breakdown by the incoming 
electrons producing several reactive oxygen species (ROS). The ROS thus produced are 
toxic to the cell and causes damage to the other cell components (Grecz et al., 1983). 
Major ROS produced includes hydroxyl radical, superoxide radical, hydrogen peroxide 
molecules etc. Cells do have innate systems such as catalase, peroxide reductase, 
superoxide dismutase which scavenges these ROS being formed (Arena, 1971). If there 
occurs sufficient indirect damage, cell death can occur by cellular leakage and complete 
cell lysis. 
Another important effect is the production of mutagenic lesions in the DNA such 
as the GO lesion (Michaels and Miller, 1992). The 8 hydroxyguanine (GO) or the 7, 8 
dihydro-8-oxoguanine (8-oxoG) refers to the damaged form of the Guanine residue in 
the nucleic acid. The GO lesions are very stable product of oxidative damage of DNA 
which can be due to ionic radiation, electron transport or lipid peroxidation. Cells have 
evolved different strategies such as GO system comprising of mutM, mutT and mutY 
genes to enhance the proof reading of the DNA polymerase III to encounter such lesions 
in the nucleic acid (Michaels and Miller, 1992).  
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Irradiated vaccines  
Ability of ionizing radiation to induce microbial inactivation has been used in the 
past to develop irradiated vaccines. Most of the studies with irradiated vaccines used 
gamma irradiation for generating inactivated bacterial or protozoan vaccines. Some of 
the early studies were conducted using gamma radiation attenuated Plasmodium berghei 
sporozoites (Nussenzwig et al., 1967), Rickettsia (Eisenberg and Osterman, 1978; 
Jerrels, 1983), Trypanosoma rhodensiense (Wellde etal., 1973). It was shown that use of 
radiation attenuated pathogens that retain their ability to infect host cells was helpful in 
improving the immune response (Bain et al., 1999).  Among the various vaccines 
developed, the most promising results were obtained from gamma attenuated 
Plasmodium sporozoites, causative organism for malaria in humans. It was shown that 
infecting murine model system with gamma irradiated mosquitoes harboring infectious 
sporozoites imparted protection (Nussenzwig et al., 1967). Rodent studies provided great 
impetus towards human studies involving radiation attenuated P. falciparum sporozoites 
(Clyde et al., 1990; Rieckmann, 1990). Immunization of human volunteers with bites of 
irradiated mosquitoes harboring P. falciparum and P. vivax sporozoites imparted 
protective immunity against challenge with infectious P. falciparum or P. vivax 
sporozoites (Hoffmann et al., 2001). This proved that gamma attenuated malaria vaccine 
provided sterile protective immunity. Recent clinical trials conducted by Seder et al. 
(2013), using intraveneous injection of gamma attenuated P. falciparum sporozoite 
imparted consistent, high level vaccine induced protection against human malaria, thus 
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becoming the first malarial vaccine to provide 100% protection against disease (Seder et 
al., 2013).  
Studies using gamma irradiated Listeria monocytogenes have shown that, unlike 
heat killed or formalin treated bacteria, irradiated L. monocytogenes preserved antigenic 
and adjuvant properties (Datta et al., 2006). It was shown that irradiated Listeria induced 
protective T cell responses, previously thought to require live infection. Irradiated 
Brucella abortus and Brucella neotomae was also found to induce high levels of cellular 
immune response and imparted protection against virulent challenge in mice model 
system (Sannakkayala et al., 2005; Moustafa et al., 2011; Magnani et al., 2009). 
Encouraging results were obtained from studies using gamma irradiated influenza A 
virus vaccine (γ-A/PC) in mice, which showed that γ-A/PC was highly immunogenic 
and elicited cytotoxic T cell responses, most likely responsible for the long lasting cross 
protective immunity against highly lethal influenza A infections (Furuya et al., 2010; 
Alsharifi, 2009). Intranasal administration of single dose of γ-A/PC conferred significant 
protection in mice against homologous and heterosubtypic virus challenge (Furuya et al., 
2010).   
With the background obtained from the gamma irradiated vaccine, the current 
study focused towards exploring a relatively novel area of using environmentally safe 
electron beam irradiation for vaccine development. Proof of concept studies were 
conducted using a widely studied pathogenic bacterium Salmonella enterica serovar 
Typhimurium.  
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Salmonella  
Salmonella are enteric bacteria that are of major clinical relevance in both 
developed and developing countries, where it causes food-borne illnesses (Scallan et al., 
2011). Salmonella are found as commensal organism or as a pathogen in various warm 
and cold blooded animals (Dougan et al., 2011). The microbe is capable of surviving 
freely for extended time period in different environments such as seawater, sewage, river 
etc. Salmonella infects both humans and animals via fecal- oral route. Salmonella is 
commonly associated with acute gut-associated non systemic gastroenteritis or 
Salmonellosis (Dougan et al., 2011, Fabrega and Vila, 2013). Certain serovars of 
Salmonella can also cause systemic infection- typhoid fever in humans and animals. 
According to CDC, approximately 40,000 confirmed cases of Salmonellosis are reported 
in the United States annually (CDC). Illness is mostly predominant in elderly, young 
children and immunocompromised individuals that results in death of approximately 400 
people per year (Scallan et al., 2011).  
Salmonella belongs to the family Enterobacteriaceae and are gram negative, 
motile, facultative anaerobic, non-lactose fermenting rod shaped bacteria (Mastroeni et 
al., 2001; Dougan etal., 2011). The genus Salmonella comprises of two species which 
are pathogenic to humans, Salmonella  enterica and S. bongori. Among the different 
species, Salmonella enterica is of prime importance as it harbors multiple serotypes that 
are pathogenic to humans and animals such as Typhimurium, Enteritidis, Typhi and 
Paratyphi. Although Salmonella can infect wide range of hosts, certain serovars are 
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restricted to specific host species and causes varied clinical symptoms. Salmonella Typhi 
causes typhoid symptoms in humans and other primates and it does not cause infection 
in mice or other rodents. Similarly, S. Paratyphi A is also restricted to humans, S. 
Gallinarum and S. Pullorum causes fowl typhoid. Salmonella Typhimurium causes 
invasive typhoid like symptoms in susceptible mice, which helps to utilize murine S. 
Typhimurium as a surrogate model for typhoid and general Salmonellosis (Dougan eal., 
2011; Hormachae, 1979). 
Salmonella pathogenesis 
Most of the current understanding on Salmonella infection and immune response 
mechanisms are obtained from murine typhoid model (Dougan et al., 2011). Several 
studies have also been carried out in other model systems such as poultry, cattle and 
even human clinical observations (Villareal ramos et al., 2000; Pullinger etal., 2007; 
Hornick et al., 1970). Salmonella is acquired in host system via ingestion of 
contaminated food or water or from a carrier. Following ingestion, a proportion of 
bacteria resists the low pH prevalent in stomach environment and reaches the small 
intestine. The adaptive acid tolerance mechanism of Salmonella helps in survival of the 
bacteria in the low pH conditions of the stomach (Muller et al., 2009). Salmonella 
establishes a luminal colonization of small and large intestine and eventually causes 
bacterial shedding for significant time period. Salmonella effects the invasion of host 
system by penetrating the mucosal epithelia. Salmonella employs a number of virulence 
genes or pathogenicity genes defined as Salmonella Pathogenicity Island- I (SP-1) to 
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gain access to epithelial cells (Dougan et al., 2011). Salmonella mediates mucosal 
penetration through different routes. The bacteria can enter through specialized epithelial 
cells called microfold cells (M cells) with the contribution of SP-1 genes (Jensen et al., 
1998; Jepson and Clark, 2001). An alternate penetration strategy involves direct 
phagocytosis of Salmonella by CD18+ cell such as dendritic cells and macrophages, 
which reaches through the epithelial barrier and pulls the bacteria to sub epithelial layers 
(Vazquez-Torres et al., 1999). Another mechanism utilizes the ability of Salmonella to 
disrupt the tight junction of epithelial layers to gain entry to mucosal epithelia (Rescigno 
et al., 2001)). Thus, this bacterim employs a a combination of different routes to effect 
mucosal penetration. 
During systemic infection, Salmonella gains entry to nonphagocytic cell such as 
epithelial cell, or phagocytic cells like macrophage and dendritic cells.  Salmonella 
subverts the normal maturation of phagosomes and transforms it to Salmonella 
containing vacuole (SCV), where the bacteria survives and eventually undergoes 
replication (Petrovska et al., 2004; Wick, 2002). Expression of a functional natural 
resistance associated macrophage protein 1 (Nramp-1) in macrophage is essential to 
restrain the Salmonella invasion in vivo (Blanden et al., 1996; Monack et al., 2004; 
Mittrucker et al., 2000). In order to survive in the endosomal compartment Salmonella 
tightly regulate virulence determinants encoded by SPI-2 genes (Ohl and Miller, 2002). 
Following infection, bacteria spread from infected cells to new infection foci such as 
lymphatic tissues, liver spleen, bone marrow where they undergo further intracellular 
replication (Mastroeni et al., 2001; Dougan et al., 2011). During fatal infection with 
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higher bacterial loads, there occurs secondary bacteremia, endotoxic shock and rapid 
death (Makela and Hormaeche, 1997). Non-fatal infection is characterized by 
splenomegaly, general macrophage mediated immune suppression which results in 
plateauing of bacterial titers. Finally, there adaptive immune response occurs imparting 
long lasting immunity against reinfection (Mittrucker et al., 2000). 
In vivo immune response to Salmonella Typhimurium 
The immune response mechanisms elicited by the host reflects the different 
stages of S. Typhimurium infection. Primary immune response to S. Typhimurium 
occurs in different phases which include early innate response and adaptive immune 
response (Makela and Hormaeche, 1997; Eisenstein, 1999). 
Innate immune response mechanisms are triggered during initial stages of 
Salmonella infection. When Salmonella gains entry to the epithelium, host cell invokes 
first set of innate immune responses targeted to ensure bacterial killing and control of 
bacterial replication. Phagocytic cells like macrophages and neutrophils are the major 
players in this phase which mediates bactericidal activities (Mittrucker et al., 2000). 
Proinflammatory cytokines such as interferon-γ (IFNγ) and tumor necrosis factor 
(TNFα) are considered as prerequisites for activating macrophages (Nauciel and 
Espinasse-Maes, 1992; Gulig et al., 1997). Activated phagocytic cells control the growth 
of virulent Salmonella using reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI) (Shiloh et al., 1999; Mastroeni et al., 2001). The cytokines IFNγ and 
TNFα also help in rendering the Salmonella containing vacuole accessible to lytic 
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effector molecules from lysosomes (Mittrucker et al., 2000). During the infection, cell 
wall components like lipopolysaccharide (LPS), triggers Toll like receptor (TLR) 
mediated inflammatory response by the production of proinflammatory cytokines such 
as TNFα, Interleukin (IL)-12, IL-18, IFNγ by phagocytes such as DC, macrophage, and 
natural killer (NK) cells (McCormick et al., 1998). TNFα is involved in granuloma 
formation, whereas IFNγ is crucial for macrophage activation and also contributes to the 
formation of focal granulomas in tissues (Mastroeni et al., 2000).  Both IL-12 and IL-18 
help to regulate IFNγ production by NK cell and also aid in down regulation of anti-
inflammatory cytokines such as IL-10 (Mastroeni et al., 1999; Mastroeni et al., 2000). 
Production of inflammatory cytokines stimulates a positive feedback loop by activating 
phagocytes to further produce inflammatory cytokines. Although the innate response 
mechanisms effectively restrict the initial bacterial growth, it alone is not sufficient to 
mediate complete bacterial elimination from the host. Moreover, Salmonella adapts to 
the innate immune mechanisms by expressing various virulence factors that provide 
resistance to bactericidal host mechanisms (Cirillo et al., 1998; Mittrucker et al., 2000). 
Hence, for effective bacterial elimination and for protection against subsequent pathogen 
encounter, it is necessary to generate Salmonella specific adaptive immune response 
mechanisms.  
Dendritic cells (DC) serve as crucial link between innate and adaptive immune 
response to Salmonella. DCs are the most efficient antigen presenting cells (APC) 
capable of internalizing and processing the bacteria, and presenting the pathogen derived 
peptide antigens to naïve T cells to initiate antigen specific adaptive immune response 
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(Sundquist et al., 2004; Yrlid et al., 2000). Upon pathogen encounter, DC undergoes 
maturation process indicated by increased surface expression of co-stimulatory 
molecules and production of proinflammatory cytokines IL-12 and TNFα. Mature DC 
migrate from peripheral tissues to secondary lymphoid organs such as lymph nodes, 
spleen, where they present Salmonella antigens to prime naïve T cells (Sundquist et al., 
2004). Antigen specific activation of T cells differentiates naïve CD4+ T cells to Th1 
cells. The major contributor of adaptive response is CD4+αβTCR+ T cells with Th1 
phenotype (Dougan et al., 2011). Th1 cells produce inflammatory cytokine IFNγ, aiding 
in recruitment of effector macrophages for antigen specific pathogen clearance 
(Mastroeni et al., 2001; Mastroeni and Menager, 2003). Th1 cells also mediate 
regulation of Salmonella specific B cell activation and maturation, resulting in 
production of isotype switched antibodies against bacterial polysaccharide and bacterial 
protein antigens (Sinha et al., 1997; Dougan et al., 2011). But, role of CD8+ T cells and 
B cells are dispensable in case of primary response. Effector B cells and T cells 
transforms to memory cells after pathogen clearance, that provide immunological 
memory against Salmonella (Hess et al., 1996; Dougan et al., 2011). Apart from Th1 
cells other T cells such as Th17 cells are also involved in immune response. Th17 help in 
recruiting neutophils, chemokines and defensins during early phase of immune response 
to trigger neutrophil influx to infection site (Liu et al., 2009). 
Secondary immune response is characterized by relatively shorter innate phase 
followed by antigen specific adaptive phase resulting in faster bacterial clearance. 
Infection triggers activation of memory cells to transform to effector cells resulting in 
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faster induction of antigen specific adaptive immune response. Concerted action of both 
CD4+ and CD8+ T cell along with anti- Salmonella antibodies is required in secondary 
immune response (Mastroeni and Menager, 2003). CD4+ T cell mediates protection 
through IFNγ mediated macrophage activation. CD8+ T cell differentiates into cytotoxic 
T cells mediating lysis of infected cell and presence of antigen specific antibodies help 
in bacterial clearance, early in the infection phase (Dougan et al., 2011). 
Vaccines against Salmonella infections 
Vaccination is an effective tool for prevention and control of Salmonella 
infections (Mastroeni et al., 2001). Broadly, Salmonella vaccines can be classified as 
whole cell killed vaccines, subunit vaccines and live attenuated vaccines (Mastroeni and 
Menager, 2003). 
Whole cell killed vaccine – Killed whole cell Salmonella vaccines are developed 
by inactivating the bacterial cultures using heat, β-propiolactone, glutaraldehyde or 
formaldehyde (Singh, 2009). Whole cell killed vaccines have been found to be 
immunogenic and induce poor cell mediated immunity (Collins, 1974; Harrison et al., 
1997). Killed vaccines were found to induce good humoral immune response, but 
insufficient Th1-type response (Thatte et al., 1993; Harrison et al., 1997). In a mice 
model, killed whole cell vaccines conferred protection against virulent challenge 
(Collins, 1974; Eisenstein et al., 1984). Killed whole cell vaccine imparted partial 
protection in chicken against intestinal colonization, fecal shedding, systemic pathogen 
spread and egg contamination (Gast et al., 1992; Mastroeni et al., 2000). In calves, killed 
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Salmonella vaccines were found to be less protective compared to live attenuated 
vaccines owing to impaired cell mediated immunity (Bairey et al., 1978; Robertsson et 
al., 1983). Killed S. Typhi elicited good antibody response and conferred moderate 
degree of protection in humans (Levine et al., 1989).  
Subunit vaccines/ Bacterial fractions – Subunit vaccines are relatively safe and 
immunogenic. Subunit vaccines like Vi polysaccharide of S. Typhi are currently licensed 
for human use (Acharya et al., 1987; Klugman et al., 1996). The immunogenicity and 
protective ability of Vi subunit vaccine can be increased by binding to certain proteins 
like tetanus toxoid, cholera toxin or diphtheria toxin (Kossaczka et al., 1999; Singh et al., 
1999). Immunization with bacterial fractions have shown moderate protection which is 
mostly achieved effectively in innately resistant animals (Mastroeni et al., 2001). 
Immunization of innately resistant mice with porins imparted protection against virulent 
challenge (Svenson et al., 1979), whereas innately susceptible mice were protected 
against challenge with moderately virulent organisms (Kuusi et al., 1979). 
Administration of S. Enteritidis outer membrane protein (OMP) with adjuvant elicits 
high antibody titer and prevents Salmonella shedding in chicken (Meenakshi et al., 
1999). Repeated immunization with naïve or alkali treated lipopolysaccharide (LPS) 
imparted protection only for innately resistant mice (Ding et al., 1990). Acid hydrolyzed 
LPS, Salmonella O-polysaccharides (O-PS) are less immunogenic in nature, but the 
immunogenicity of O-PS was found to increase when conjugated with protein carriers 
like tetanus toxoid, diphtheria toxin, porin etc. (Watson et al., 1992).  
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Inactivated Salmonella vaccines like killed whole cell vaccines and subunit 
vaccines confer protection against reinfection by inducing strong antibody response. 
They induce IL-4 dominated Th2 type immune response with low levels of delayed type 
hypersensitivity (DTH) and high levels of Salmonella specific antibodies of IgG1 
isotype (Thatte et al., 1993; Galdiero et al., 1998; Mastroeni and Menager, 2003). 
Live attenuated Salmonella vaccines – Live attenuated vaccines are 
immunogenically superior to inactivated vaccine due to their ability to induce cell-
mediated immune response in addition to antibody response. Attenuated live Salmonella 
are generated either by inducing undefined mutations or defined mutations. Availability 
of the complete genome sequence of S. Typhimurium and S. Typhi has helped in 
generating very specific defined mutants which serve as potential vaccine candidates. 
Various Salmonella genes that have been targeted for attenuated vaccine development.     
A detailed list of various live attenuated Salmonella vaccine candidates is provided in 
table 2-3. Immunization with live attenuated Salmonella induces long lasting protective 
immunity and involves recall of immunological memory (Killar and Eisenstein, 1985; 
Hormaeche et al., 1991; Mastroeni etal., 1992). Cellular responses are of Th1 type, 
indicated by the DTH and production of proinflammatory cytokine IFNγ upon 
restimulation by immune T cells (Harrison et al., 1997; Sztein et al., 1994; Mastroeni 
and Menager, 2003). For long lasting protective immunity, live attenuated vaccine 
employs both humoral and T cell mediated immunity which is responsible for the 
superior potential of vaccines compared to inactivated Salmonella vaccines (Mastroeni 
et al., 2001; Mittrucker and Kaufmann, 2000).  
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Table 2-3. List of live attenuated Salmonella vaccine candidates developed and tested in humans and animals 
 
Type of mutation/ 
attenuation 
Salmonella 
strains/ 
serovars 
Host Comments Reference 
Early live attenuated vaccines 
Chemical or ultra violet 
mutagenesis (Temperature 
sensitive mutants- TS) 
S. Enteritidsis,   
S. 
Typhimurium, 
S. Typhi 
Mice, 
humans 
Induced anti-Salmonella antibodies, imparted 
protection against virulent Salmonella challenge 
in mice. TS S. Typhi was poorly immunogenic 
in humans 
Gheradi etal., 1993; 
Nauciel, 1990; 
Bellanti et al., 1993 
Streptomycin dependent 
mutants 
S. Typhi Humans 
Safe and immunogenic (increased antibodies) in 
humans. Lyophilization drastically reduced 
vaccine efficiency 
Levine etal., 1976 
Undefined Salmonella mutant  
(S. Gallinarum 9R) 
S. Gallinarum Chicken 
Afforded protection against virulent S. 
Gallinarum and S. Enteritidis. Induced only 
poor protection against S. Typhimurium 
Smith, 1956;        
Silva et al., 1981 
Adaptation in nonspecific host 
or some specific growth 
media 
S.Dublin Strain 
51 
Calves 
Induced cell mediated and humoral response 
and provided protection in calves compared to 
killed bacterins 
Meyer et al., 1992 
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Table 2-3. Continued, List of live attenuated Salmonella vaccine candidates developed and tested in humans and 
animals 
 
Galactose epimerase-less mutants 
galE mutant 
S. 
Typhimurium 
Mice, 
calves 
Significantly reduced fecal shedding with 
homologous challenge. No significant humoral 
immune response 
Hone et al., 1987; 
Wray et al., 1977 
Nitrosoguanidine (NTG) 
induced undefined galE 
mutant 
S. Typhi 
(Ty21a) 
Humans 
Currently used as live vaccine in humans. 
Elicits local and systemic humoral immunity 
and cellular immune response. Confers 
significant although incomplete protection from 
typhoid. Being an undefined mutant, it’s 
difficult to determine genetic basis of 
attenuation 
Gilman et al., 1977; 
Cryz et al., 1993; 
Kantele et al., 1986; 
Levine et al., 1989 
Auxotrophic mutants         
aroA mutant 
S. 
Typhimurium, 
S. Enteritidis.    
S. Dublin,           
S. Gallinarum 
Mice, 
calves, 
chicken, 
calves, 
Swine 
Induces good cell mediated and humoral 
immunity. Imparts long lasting protection 
against re-challenge. Can cause slow 
progressive lethal infection in severely 
immunocompromised animals. 
Hoiseth and Stocker, 
1981; Killar and 
Eisenstein, 1985; 
Cooper et al., 1994; 
Griffin and Barrow, 
1993;       Lumbsden 
et al., 1991 
aroA aroC double mutant 
S. 
Typhimurium, 
S. Typhi (Ty2) 
Mice, 
humans 
Introduction of mutations of more than one 
genes reduces chance of virulent reversion. 
Induces protection against virulent challenge.  
Dougan et al., 1988; 
Chatfield et al., 1992 
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Table 2-3. Continued, List of live attenuated Salmonella vaccine candidates developed and tested in humans and 
animals 
 
aroA aroD double mutant 
S. 
Typhimurium 
Calves Provided efficient and safer protection to calves Jones et al., 1991 
aroC aroD double mutant S. Typhi (Ty2) Humans 
Provided humoral and cell mediated immunity. 
But, induced undesirable reactions with mild 
transient bacteremia in a proportion of human 
subjects 
Tacket et al., 1992; 
Sztein et al., 1994 
Purine gene mutants 
 
purA mutant 
S. 
Typhimurium 
Mice 
Induced cell mediated and antibody response, 
but was ineffective as oral or parenteral 
vaccines 
McFarland and 
Stocker, 1987 
aroA purA double mutants 
S. Dublin, S. 
Typhi 
Mice, 
humans 
Reduced ability to colonize, poorly 
immunogenic 
Sigwart et al., 1989; 
Levine et al., 1987; 
Stocker et al., 1988 
purE mutant 
S. 
Typhimurium 
Mice 
Moderately attenuated, can induce formation of 
liver abscesses  
Everest et al., 1997 
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Table 2-3. Continued, List of live attenuated Salmonella vaccine candidates developed and tested in humans and 
animals 
 
htr mutants         
htrA mutants 
S. 
Typhimurium,  
Mice, 
calves 
Imparted protection against virulent challenge 
in mice. But, oral administration resulted in 
fatal disease in calves 
Strahan et al., 1992; 
Villareal-Ramos et 
al., 2000 
htrA aroaA double mutants 
S. 
Typhimurium 
Mice 
Confers good protection against challenge in 
mice 
Chatfield et al., 1992 
aroC aroD htrA triple mutants S. Typhi Humans 
Induced Salmonella specific antibodies as well 
as cell mediated responses. Relatively safer in 
human volunteers 
Tacket et al., 1997 
cya crp mutants         
cya crp double mutants 
S. 
Typhimurium, 
S. 
Choleraesuis, 
S. Typhi 
Mice, 
chicken, 
swine, 
humans 
Imparted humoral and cell mediated response in 
chicken. Impaired ability to invade/ survive in 
mice spleen. Developed cell mediated response, 
but impaired humoral response in swine. A 
small proportion of human volunteers 
developed fever and bacteremia after 
vaccination  
Curtiss and Kelly, 
1987;            Hassan 
and Curtiss, 1990;              
Stabel et al., 1993; 
Tacket et al., 1992 
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Table 2-3. Continued, List of live attenuated Salmonella vaccine candidates developed and tested in humans and 
animals 
 
phoP/phoQ mutants         
phoP/phoQ mutants 
S. Typhiurium, 
S. Typhi 
Mice, 
humans 
Induces cell mediated immunity in mice, but 
inefficient in growing in mice spleen. Found to 
be relatively safe and immunogenic in human 
volunteers 
Galan and Curtiss, 
1989;             Miller, 
1991;  
aroA phoP/phoQ mutants S. Typhi Humans 
Found to over attenuated and poorly 
immunogenic 
Hohmann et al., 
1996 
Other mutants         
dam mutants 
S. 
Typhimurium 
Mice Totally avirulent and induce effective protection  Heithoff et al., 1999 
surA mutants 
S. 
Typhimurium 
Mice Induce protective immunity in mice 
Sydenham et al., 
2000 
nuoG mutants S. Gallinarum Chicken 
Reduces colonization in caeca, liver and spleen. 
Reduces mortality 
Zhang-Barber et al., 
1998 
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Electron beam irradiated Salmonella vaccines  
The National Center for Electron Beam Research (NCEBR) at Texas A&M 
University has been at the forefront of developing different applications for high energy 
electron beam (eBeam) irradiation technology. Over the past few years, the Center in 
collaboration with the USDA-ARS in College Station has demonstrated that eBeam 
irradiation can be used to develop immuno-modulators that can have commercial value 
as vaccines in poultry (Kogut et al., 2012 and Jesudhasan et al., 2010). The basic 
technology is currently under US patent protection (US patent 8,173,139).  
Studies have been conducted with eBeam irradiated S. Typhimurium (ST) and S. 
Enteritidis (SE) to check the effectiveness of the immunomodulators in chicken (Kogut 
et al., 2012; Jesudhasan et al., 2010). It was showed that intramuscular administration of 
eBeam irradiated SE to laying hens, imparted protection against virulent SE challenge 
(Jesudhasan et al., 2010).  Significant reduction in colonization of SE in liver, ceca, 
spleen and ovary was observed which was attributable to the increased Salmonella 
specific IgG levels in the birds. Studies by Kogut et al. (2011) were focused towards 
reducing intestinal colonization and shedding of ST in neonatal chickens. The study 
demonstrated that in ovo administration of eBeam irradiated ST provided protective 
intestinal colonization inhibition effect against homologous Salmonella challenge. They 
observed that the increased resistance to Salmonella infections by vaccinated birds was 
concomitant with the augmented functional innate immune response by chicken 
heterophils. Findings from the bird studies indicate that eBeam vaccine technology is an 
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enabling platform technology to create high potency formulations that can serve as 
veterinary and human vaccines. Therefore, the next step was to study microbiological 
and immunological characterization of the eBeam irradiated vaccine to gain deeper 
understanding about the immune response mechanism by which protection is provided 
by eBeam vaccines. 
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CHAPTER III 
MATERIALS AND METHODS 
 
Bacterial strains 
The Salmonella enterica serovar Typhimurium strain ST14028 was used for 
eBeam irradiation (EBST).  The S. Typhimurium strain 14028, aroA- (del-STM0978:: 
KanR; aroA null) was used as the live attenuated bacteria control (AroA) for mice 
immunization studies. The stationary phase cultures were prepared by growing bacterial 
cells overnight at 37°C in Tryptic Soy Broth (BD Diagnostic Systems, Sparks, MD). The 
overnight bacterial cultures were washed twice and re-suspended in phosphate buffered 
saline (PBS) (Sigma Aldrich, St. Louis, MO).  The optical density of the bacterial 
cultures was adjusted to ~1.0 (~1x 109 CFU/ml) and used for eBeam irradiation studies 
and heat inactivation studies. Bacterial enumeration was carried out by plating the 
serially diluted samples on Tryptic soy agar plates. For heat killed antigen (HKST) 
preparation, bacterial suspension containing ~1x 109 CFU/ml was heat inactivated at 
70°C for 1 h. 
Animals 
Six to eight weeks old female C57BL/6J mice were obtained from Jacksons 
Laboratory (Bar Harbor, Maine). All the mice were housed in specific pathogen free 
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conditions and were cared according to the Texas A&M University Institutional Animal 
Care and Use Committee guidelines. 
Electron beam irradiation and dose optimization  
For eBeam irradiation trials, stationary phase S. Typhimurium (~ 1x 109 CFU/ml) 
cells that were resuspended in PBS were used. Aliquots (10 ml) of the bacterial 
suspension was packaged (in triplicate) in Whirl-Pak® bags (Nasco, New York, NY) and 
heat sealed. Each heat-sealed Whirl-Pak® bag in turn was triple bagged to meet the 
University regulations regarding handling potentially bio hazardous samples at the 
eBeam irradiation facility. The eBeam irradiations were performed at the National 
Center for Electron Beam Research on Texas A&M University campus using a 10 MeV 
linear accelerator. In order to study the inactivation kinetics, samples were subjected to 
different target eBeam doses ranging from 0.2 – 8 kGy.  Irradiation dose measurements 
were performed using alanine dosimetry that was validated to international standards.  
The dosimeters (Harwell Dosimeters, Oxfordshire, UK) were measured using the Bruker 
E-scan spectrometer (Bruker, Billerica, MA). The measured doses were used for data 
plotting and calculation of inactivation kinetics (Praveen et al., 2013).  
Confirming inability of bacterial growth   
The inability of lethally irradiated bacteria to replicate was verified under in vitro 
and in vivo conditions. The eBeam irradiated S. Typhimurium cells were incubated in 
TSB at 37°C and room temperature (25°C) for up to 10 days and scored for visual 
evidence of cell multiplication. The multiplication of eBeam irradiated Salmonella cells 
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in culture media was verified by plating aliquots (200 µl) on TSA plates.  Counts of 
EBST were taken using Petroff-Hausser counting chamber (Hausser Scientific, 
Horsham, PA) at defined times during culture to check multiplication of non culturable 
S. Typhimurium. Bacterial cells were loaded to Petroff-Hausser counting chamber and 
visualized under dark field using a phase contrast microscope, Nikon Optishot 2.  Based 
on inactivation kinetics as well as the inability of bacterial regrowth, eBeam dose of 7 
kGy was used for generating eBeam irradiated S. Typhimurium vaccine (EBST).  
The possible multiplication of EBST under in vivo condition was studied using 
C57BL/6J mice, an innately susceptible mice model for S. Typhimurium (Pie et al., 
1997). Three groups of mice (5 mice/ group) were orally gavaged with 1 x 108 CFU of 
EBST (EBST mice), 1 x 108 CFU live Salmonella Typhimurium (live ST mice) and 200 
µl of PBS (sham mice). The mice were observed for presence of any disease symptoms 
and mortality. The fecal samples (~0.1g/ mouse) were collected from individual mouse 
on day 3, 7, 10 and 14, post oral gavage. Homogenized fecal samples were plated on 
Xylose Lysine deoxycholate (XLD) plates, selective for Salmonella sp.. After 14 days of 
oral gavage, mice were euthanized. The liver, spleen, mesenteric lymph nodes and 
cecum from the EBST fed mice were homogenized and plated on XLD plates.  
Cell membrane integrity assessment 
The integrity of the cell membranes of the EBST was visually verified using the 
LIVE/DEAD® assay. This assay was performed using the BacLight™ Bacterial viability 
kit for microscopy (Molecular Probes, Eugene, OR). The green fluorescent SYTO®9 and 
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the red fluorescent propidium iodide nucleic acid stains were used to stain the EBST, 
HKST and live ST cell preparations as per manufacturer’s protocol. Briefly, components 
A (SYTO®9) and B (propidium iodide) were mixed in ratio 1:1 and 3µl of dye mixture 
was added to 1 ml of bacterial suspension. The bacteria-dye suspension was mixed 
thoroughly and incubated at room temperature for 15 min. After incubation, 5 µl of 
bacterial suspension was placed on a clean glass slide, covered with a cover slip and 
observed under Nikon Eclipse 80i fluorescence microscope.  
Electron microscopic examination of cell surfaces  
To understand the ultrastructural changes that occur after eBeam irradiation, the 
EBST, live and HKST cells were examined using Scanning Electron microscopy (SEM) 
and Transmission electron microscopy (TEM). Live and heat-killed S. Typhimurium 
samples were examined for comparing the structural differences. All samples were 
preserved by mixing equal volume of sample with a fixative containing 4% 
glutaraldehyde prepared in 100mM phosphate and 100mM sucrose, pH 7.4. The fixed 
samples were rinsed twice in a wash buffer (50 mM phosphate, 50 mM sucrose, pH 7.4) 
by centrifugation at 1600 x g for 10 min and resuspended in a small wash buffer volume. 
A 50 µl aliquot of the sample was placed on 0.1% poly-L-lysine coated glass coverslips 
and incubated at room temperature for 60 min.  The samples were fixed to the coverslips 
by immersion in 3% glutaraldehyde fixative for 60 min, followed by post-fixation in 1% 
OsO4 prepared in 100 mM phosphate and 100 mM sucrose, pH 7.4 for 90 min at 4°C.  
The coverslips were dehydrated and critical point dried in CO2.  The dried samples were 
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then sputter-coated with gold and examined in a Hitachi H7110.  The remaining portions 
of the samples were pelleted in 2.5% agar, post-fixed in 1% OsO4 as above, and post-
stained overnight in 0.5% aqueous uranyl acetate, dehydrated and embedded in 
Mollenhauer’s mixture of epoxy resin (Mollenhauer et al., 1964). Thin sections of 
embedded samples were examined in a Hitachi H7000.   
Determination of bacterial motility 
Motility assessment was carried out by means of a comparative scoring between 
EBST and live S. Typhimurium. Wet mounts of bacterial samples were visualized using 
Phase contrast microscope (Nikon Optishot 2). Negative staining was carried out to 
specifically examine presence of bacterial flagella on EBST. A drop of EBST bacterial 
suspension was placed on a carbon coated 300 mesh copper grid and allowed to stand for 
30 seconds. Further, the grid was decanted and replaced with a drop of negative stain 1% 
phosphotungstic acid (Sigma Aldrich, St. Louis, MO) for 30 seconds, and excess stain 
was removed and the grid was allowed to dry. The stained grids were examined using a 
Hitachi H-700 Transmission electron microscope. 
Immunoreactivity profile of EBST to Salmonella antibodies 
Salmonella specific immunoreactivity profile of EBST was compared with non-
irradiated and heat killed S. Typhimurium using immunoblotting. After eBeam 
irradiation, bacterial samples were stored at room temperature, 4°C, -20°C and 
lyophilized condition. After one month of storage at indicated conditions, total soluble 
protein was extracted using B-PER Bacterial protein extraction reagent (Thermo 
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Scientific, Rockford, IL) according to manufacturer’s protocol. Briefly, bacterial cells 
were pelleted by centrifugation at 5000 x g for 10 minutes.  To the bacterial pellet, B-
PER reagent (Thermo Scientific, Rockford, IL) was added (4 ml reagent/ g of cell 
pellet), supplemented with lysozyme (2 µl/ ml) and DNase I (2 µl/ ml). After mixing, the 
bacterial suspension was incubated for 10 min at room temperature. The lysate was 
obtained by centrifuging the bacterial suspension at 12,000 x g for 5 min. Protein 
extraction was also carried out from overnight culture of S. Typhimurium and heat killed 
S. Typhimurium for comparison. The extracted proteins were quantified using Pierce 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL) according to manufacturer’s 
instruction. The extracted proteins were separated under reducing conditions on an SDS 
PAGE gradient (4-20%) gel (Precise Protein Gel, Thermo Scientific) and subsequently 
transferred to PVDF membrane for western blot analysis (Laemmli, 1970). The 
membrane was blocked overnight at 4°C using 5% BSA in TBST (Sigma Aldrich, St 
Louis, MO). The membrane was washed twice with TBST and incubated with primary 
antibody for 2 h at room temperature. Immune serum from mice, previously immunized 
with Salmonella  Typhimurium (a kind gift from Dr. R.C. Alaniz, Texas A&M Health 
Science Center, College Station, TX) was used as primary antibody (1/1000 dilution).  
Following incubation, membrane was washed 4 times in TBST and incubated at room 
temperature for 1 h, with 1/ 20,000 dilution of alkaline phosphatase conjugated sheep 
anti mouse IgG F(ab`)2 fragment (Sigma Aldrich, St Louis, MO). Further, the membrane 
was washed 4 times with TBST and developed using chromogenic reagent, NCP/ BCIP 
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(Thermo Scientific, Rockford, IL). Excess of chromogenic reagent was washed off using 
deionized water and the membrane was dried and digitally recorded. 
Determination of bacterial metabolic activity 
The metabolic activity of EBST was assessed using Alamar Blue® reagent (Life 
Technologies, Carlsbad, CA) which quantitatively measures the reducing environment 
present within the cell (Magnani et al., 2009; Moustafa et al., 2011). Alamar Blue® 
system incorporates a non-toxic, cell permeable, non-fluorescent, blue colored redox 
indicator, resazurin. In metabolically active cells maintaining a reduced cell 
environment, resazurin gets reduced to highly fluorescent red colored compound called 
resorufin. The conversion of resazurin to resorufin by the metabolically active cells can 
be quantitatively measured by measuring the increase in fluorescence. After eBeam 
irradiation, bacterial samples were stored at 4°C and the persistence of metabolic activity 
in the eBeam irradiated S. Typhimurium was monitored for 10 days. Non-irradiated S. 
Typhimurium and heat killed S. Typhimurium were used as controls for metabolic 
activity monitoring. Ninety microliters of EBST, HKST and live ST samples were mixed 
with 10µl of Alamar blue reagent and incubated at 37°C for 1 h. After incubation 
fluorescence was monitored at 530-560 nm excitation wavelength and 590 nm emission 
wavelength using Wallac 1420 VICTOR 2™ plate reader (PerkinElmer, Waltham, MA).   
Biochemical assays were performed to confirm the presence of metabolic activity 
in irradiated S. Typhimurium. The ability of bacteria to ferment specific carbohydrate in 
the media was tested by incubating EBST and HKST in Phenol Red Broth supplemented 
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with Sucrose at 37°C for 2 days. Overnight cultures of live S. Typhimurium and E. coli 
were used as controls. The color change in the media, turbidity and gas production as a 
result of bacterial metabolism were monitored. Presence of catalase enzyme in the 
irradiated cells was detected using catalase test. Catalase enzyme converts hydrogen 
peroxide to water and oxygen resulting in bubble formation. On a clean glass slides, 
EBST and live ST cells were smeared and a drop of hydrogen peroxide was added. 
Bubble formation from the bacterial preparations was monitored to detect catalase 
activity. 
Dendritric cell culture and Bone marrow dendritic cell harvest 
The murine dendritic cell line DC2.4 was cultured in Dulbecco’s Modified 
Eagles Medium (DMEM) with high glucose and L-Glutamine supplemented with 5% 
fetal calf serum, penicillin and streptomycin (100U/ml), Non-essential amino acids and 
10mM HEPES at 37°C, 5% CO2. All the media components for dendritic cell (DC) 
culture and harvest were obtained from Life Technologies, Carlsbad, CA. 
 The mouse bone marrow derived dendritic cells (BMDC) were cultured from the 
bone marrow obtained from the femurs of naïve C57BL/6J mice. Under aseptic 
conditions, the bone marrow from femurs was flushed into RPMI Complete media 
(RPMI-C). The RPMI-C medium consisted of RPMI 1640 Medium containing 
GlutaMAX™ Supplement and HEPES, supplemented with 10% heat inactivated FCS, 
50 µM 2-mercaptoethanol, 100 U/ ml penicillin and 100 U/ml streptomycin (Pen/Strep) 
and 50µg/ml Gentamicin. The cells were further spun and re-suspended in ACK lysis 
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buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA-Na2) (Sigma Aldrich, St Louis, 
MO) for RBC lysis. After the lysis of RBC, bone marrow cells were centrifuged, 
resuspended in RPMI-C media supplemented with 40 ng/ml Recombinant Mouse 
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) (R&D Systems, Inc., 
Minneapolis, MN) and strained using a 70 µm cell strainer to obtain single cell 
suspension. On day 0, ~4x 106 cells/well were plated on 6 well cell culture plates (BD, 
Franklin Lakes, NJ) with RPMI-C+ GM-CSF (40ng/ml) media and cultured at 37°C, 5% 
CO2. On day 2, 4 and 6 granulocytes and non-adherent cells were removed from the 
wells by aspirating portions of spent media. The wells were replenished with fresh 
RPMI-C+ GM-CSF (40 ng/ml) media and cultured at 37°C, 5% CO2. On day 7, semi-
adherent BMDC were harvested from the wells, centrifuged, re-suspended in RPMI-C + 
GM-CSF (20 ng/ml), and used for BMDC stimulation assays. 
In vitro dendritic cell (DC) stimulation assay 
DCs (DC2.4 cells or BMDC) were seeded in 96 well U bottom tissue culture 
plate (BD, Franklin Lakes, NJ) at 2 x 105 cells per well. DCs were co-incubated with 
indicated titrations of stimulants such as eBeam ST, heat killed ST, and viable live ST. A 
commercial ST vaccine (Salmune®, Ceva biomune, Lenexa) formulation was also 
included as a control for BMDC stimulation. Plates with DCs pulsed with the stimulants 
were incubated at 37°C, 5% CO2 for 24 h. For intracellular cytokine staining (ICS), the 
DCs were co-incubated with all the above mentioned stimulants along with 1/1000 
dilution of Protein transport inhibitor containing Brefeldin A (BD GolgiPlug™, BD 
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Biosciences, San Jose, CA) at 37°C, 5% CO2 for 4 h. After indicated incubation time, 
DCs were surface stained or subjected to ICS to detect the expression levels of surface 
markers such as CD11c in case of BMDC, MHC-II, CD40, CD80, CD86 and 
proinflammatory cytokine TNFα.  
Vaccine potency assessment 
The potential of EBST to induce maturation of dendritic cells was used as a 
parameter to assess the vaccine potency upon storage at different temperature conditions 
over longer period of time. After eBeam irradiation, EBST samples were stored at room 
temperature, 4°C, -20°C and lyophilized condition for up to 6 months. Two independent 
lots of irradiated samples were stored. The EBST lots were tested for vaccine potency on 
a monthly basis using in vitro DC stimulation assays with DC2.4 cell line. 
Mice immunization and challenge 
Mice were immunized with 2x109 EBST and the live attenuated, AroA 
suspended in PBS at 8 weeks of age. The immunization was performed by oral gavage 
with feeding needles (22 x 11/2 with 1.25 mm ball; Popper & Sons, NY). Mice were diet 
restricted 5 h before oral infection. A SHAM control group and naïve mice control group 
were also maintained, which were fed with PBS. For the EBST immunized mice, 2 
booster doses were given with 2x109 EBST at 2 weeks intervals. The mice were 
observed for the appearance of symptoms of infection or scored for mortality.  After 14 
weeks of primary immunization, mice from EBST, AroA and SHAM group were 
challenged via oral route with ~ 1x108 virulent nalidixic acid resistant Salmonella 
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Typhimurium strain ST14028. At 3 days and 7 days post challenge, the mice were 
sacrificed and liver, spleen, mesenteric lymph nodes (MLN), cecum and serum were 
harvested. Organs from individual mice were homogenized using motorized 
homogenizer (Omni International, Kennesaw, GA) in sterile PBS with 1% TritonX-100 
(Sigma Aldrich, St. Louis, MO). The homogenates were serially diluted and plated in 
TSA supplemented with 30 mg/L of nalidixic acid (Sigma Aldrich, St. Louis, MO). 
In vitro restimulation  
The spleens harvested from the mice were divided into equal halves and one half 
was used for harvesting splenocytes.  Splenocytes were harvested from individual mouse 
from the EBST, AroA, and the SHAM treatment groups. The spleen was squeezed 
between frosted ends of sterilized glass slides and the cells were collected in RPMI-C 
media supplemented with 10% FCS. The splenocytes were centrifuged and subjected to 
RBC lysis using ACK lysis buffer. After RBC lysis, splenocytes were centrifuged at 
1300 rpm and strained using 40 µm cell strainer to obtain a single cell suspension of 
splenocytes. The splenocytes were counted after trypan blue staining using 
hemocytometer. Approximately, 2x106 splenocytes were seeded per well on 96 well U 
bottom tissue culture plate and coincubated with indicated titers of stimulants such as 
EBST, HKST and anti-murine CD3e antibody (clone 145-2C11) at 37°C, 5% CO2 for 24 
h.  
 
 
49 
 
Surface staining and intracellular cytokine staining 
The upregulation of cell surface markers on DCs (DC2.4 cells or BMDC) and 
splenocytes in response to the stimulants were detected using surface staining. The ICS 
was used to detect cytokine production in response to in vitro stimulation. After 
indicated incubation time of 24 h (surface staining) and 4 h (ICS), the DCs were washed 
twice with PBS supplemented with 0.5% BSA (Sigma Aldrich, St. Louis, MO) (PBSA). 
Surface staining was done with monoclonal anti-mouse antibodies such as Phyco 
erythrin (PE) labeled murine CD11c (clone N418), Allo phycocyanin (APC) labeled 
CD40 (clone 3/23), APC labeled CD80 (clone 16-10A1), Alexa Fluor® 700 labeled 
CD86 (clone GL1), eFluor® 450 labeled MHCII (clone AF6-120.1). Surface stained 
cells were fixed using 2% paraformaldehyde and permeabilized with Perm/wash buffer 
(BD Biosciences, San Jose, CA). Monoclonal anti-mouse antibodies against 
proinflammatory cytokine TNF, Alexa Fluor® 700 labeled TNF (clone MP6-XT22) 
were used for staining the permeabilized DCs. Stained DCs were further washed and re-
suspended in PBSA and stored at 4°C in dark until analysis by flow cytometry.  
In case of in vitro restimulation of splenocytes, Brefeldin A was added at 1/1000 
dilution during the final 6 h of incubation. After 24 h of incubation, splenocytes were 
washed twice with PBSA and surface stained in the presence of Fc block (clone 2.4G2) 
with monoclonal anti mouse antibodies Pacific Blue™ labeled CD4 (clone RM4-5) and 
FITC  labeled CD8a (clone 53-6.7). Following staining, splenocytes were fixed and 
permeabilized with Cytofix/Perm buffer (BD Biosciences, San Jose, CA). Monoclonal 
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anti mouse antibodies Alexa Fluor® 647 labeled IFNγ (clone XMG1.2) and PE labeled 
TNF (clone MP6-XT22) were used to stain the permeabilized splenocytes for detecting 
the cytokines. Stained cells were finally washed and resuspended in PBSA and stored at 
4°C in dark. For all the in vitro stimulation assays, unstimulated cells and unstained cells 
were maintained as controls. All the flow cytometry reagents and antibodies were 
purchased from BD Pharmingen, San Jose, CA.    
Flow cytometric analysis 
Multi parameter flow cytometry was performed using BD FACSAria™II (BD, 
Franklin Lakes, NJ) and data acquired with BD FACSDiva™ software (BD, Franklin 
Lakes, NJ). Flow cytometric data analysis was carried out with FlowJo software (Tree 
Star, San Carlos, CA).  
Serum IgG measurement 
Blood collected from individual mice from EBST, AroA and SHAM group were 
allowed to clot at room temperature. After centrifugation, serum was collected without 
disturbing the pelleted clots and stored at -20°C until use. Indirect ELISA was performed 
for detection of antigen specific antibodies in mice sera. Nunc Maxi Sorp® flat bottom 
96 well plates (eBioscience, Inc., San Diego, CA) were coated with EBST (2x107/well) 
using coating buffer (Sigma Aldrich, St. Louis, MO) and incubated overnight at 4°C. 
Plates were washed using PBS with 0.5% Tween 20 (PBST) (Sigma Aldrich, St. Louis, 
MO). After washing, the plates were blocked using 5%Bovine Serum Albumin (BSA) in 
PBST and incubated at room temperature for 1 h. Appropriate dilutions (1/500) of mice 
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serum samples were added to the wells (150 µl/well) in triplicates and incubated at 37°C 
for 1 h. Serum from previously immunized Salmonella immune mouse was used as a 
positive control for ELISA. Following incubation, plates were washed 4 times with 
PBST and 150 µl/well secondary HRP conjugated anti mouse IgG (Jackson 
ImmunoResearch, West Grove, PA), was added to wells at appropriate dilutions 
(1/5000) in blocking buffer. The plates were incubated with secondary antibody at room 
temperature for 1 h and washed 4 times with PBST. Acetate buffer was added to the 
wells for 2-5 minutes and removed. Plates were further developed by adding 100 µl/well 
TMB substrate (BD, Franklin Lakes, NJ) and incubating for 30 min at room temperature. 
Reaction was stopped using 2M H2SO4 and the color development was measured by 
measuring the absorbance at 450nm (OD450) on Wallac 1420 VICTOR 2™ plate reader 
(PerkinElmer, Waltham, MA). Sample to positive control ratio (S/P) was calculated as 
per the following equation. Normalizing the ELISA absorbance readouts as S/P ratio 
reduces the plate variability when comparing the absorbance readings between different 
ELISA plates. 
𝑆
𝑃
𝑟𝑎𝑡𝑖𝑜 =
(𝑆𝑎𝑚𝑝𝑙𝑒 𝑂𝐷450 − 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑂𝐷450)
(𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑂𝐷450 − 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑂𝐷450)
 
Statistical analysis 
Unless otherwise stated all the data graphs and statistical analysis were generated 
using GraphPad Prism version 5.0 (GraphPad Prism software, La Jolla, CA). For 
calculating the inactivation kinetics of S. Typhimurium subjected to different eBeam 
doses, a survivor curve was plotted. The plate counts were transformed into log10 values. 
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These log10 values of the survivors were plotted against the measured eBeam doses and a 
linear regression analysis was performed. The D10 value was calculated by calculating 
the negative reciprocal of regression slope. For the mice challenge study, Kaplan meir 
curve was plotted to do the survival analysis. Kruskal Wallis one way ANOVA was used 
for statistical comparison of bacterial colonization between different treatment mice 
groups.  In case of in vitro re-stimulation assays, for determining antigen specific T cell 
responses, two tailed student’s t-test was used to compare different treatment mice 
groups for each antigen at indicated time points. For all the statistical analysis 
significance was set at p≤ 0.05. 
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CHAPTER IV 
RESULTS 
 
Electron beam inactivation of Salmonella Typhimurium  
The first step in characterizing the eBeam irradiated vaccine was to determine the 
optimum eBeam dose that will ensure complete inactivation of S. Typhimurium (ST). 
Inactivation kinetics of eBeam irradiation was studied by exposing high titers of ST (~1x 
109 CFU/ml) to incremental eBeam doses. Reduction in viable colony forming units 
(CFU) of ST was observed with an increase in eBeam dose exposure (Figure 4-1). The 
dose required for achieving 90% reduction (D10 value) of ST in PBS was calculated as 
0.19 kGy. In order to study complete inactivation, bacterial cultures (~1x 109 CFU/ml) 
were subjected to higher eBeam doses of 6, 7 and 8 kGy. No surviving viable ST was 
detected after irradiation with any of the high eBeam doses, which ensured complete 
inactivation of ST. 
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Figure 4-1. Electron beam irradiation induces S. Typhimurium inactivation. 
Inactivation kinetics of S. Typhimurium exposed to different doses of eBeam irradiation. 
For each indicated doses of eBeam exposure, viable bacterial counts were obtained by 
plating tenfold serial dilution of irradiated bacterial samples on TSA plates.D10 value 
was calculated using the negative reciprocal of regression slope of the inactivation curve. 
The arrow represents the lethal eBeam dose used to generate eBeam vaccine. 
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EBST is unable to grow under in vitro and in vivo conditions 
Regrowth studies were conducted to examine the ability of EBST to grow and 
multiply, by culturing the irradiated bacterial cells under different conditions to promote 
bacterial growth. Aliquots of ST irradiated at eBeam doses of 4, 5, 6 and 7 kGy were 
inoculated into TSB, a non-selective media and incubated at 37°C and room 
temperature. The bacterial regrowth was monitored on a daily basis by plating the 
incubated bacterial cultures on TSA plates.  It was noticed that bacteria irradiated at 
eBeam doses of 4 and 5 kGy showed regrowth whereas, bacterial samples subjected to 
higher doses of eBeam irradiation such as 6 and 7 kGy did not regrow. Bacterial growth 
on TSA plates is an indication of the presence of culturable bacterial cells. Hence it was 
confirmed that no culturable ST was present, when exposed to an eBeam dose of 7 kGy. 
To test for the possible multiplication of non culturable EBST in TSB, bacterial counts 
were made using Petroff-Hausser counting chamber on day 0 and 2 (Table 4-1). 
Bacterial counts obtained from the Petroff-Hausser counting chamber were compared 
and it was observed that there was no increase in the number of eBeam irradiated 
bacteria upon incubation in TSB media for 2 days. Hence, it was concluded that at an 
irradiation dose of 7 kGy, ST is unable to multiply even under the most favorable in 
vitro conditions.  
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Table 4-1.  Inability of eBeam irradiated S. Typhimurium to multiply in vitro in a 
regrowth media, determined using Petroff- Hausser counting chamber 
 
Days in culture Bacterial counts  
Day 0 1.14 x 109 cells/ml 
Day 2 7.1 x 108 cells/ml 
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The inability of lethally irradiated ST to multiply in vivo was tested using a 
Salmonella susceptible mice model, C57BL/6J (Pie et al., 1997). Five mice were orally 
inoculated with 1x 108 CFU of eBeam irradiated ST (EBST mice). Their fecal droppings 
were collected on regular intervals and plated on Salmonella selective media XLD to 
verify whether viable ST was shed by the mice. Two control groups of mice were also 
maintained which were gavaged with live S. Typhimurium (live ST mice) and PBS 
(sham mice) respectively. Results showed that Salmonella shedding was observed only 
in live ST mice (~ 4 log CFU/ g fecal pellet) (Table 4-2). In case of EBST mice and 
sham mice, no detectable Salmonella colonies were observed in any of the fecal samples 
collected over 14 days, indicative of the absence of viable bacterial regrowth. The 
Salmonella inoculum dose was also found to be safe for C57BL/6J mice as no mortality 
or disease symptoms were observed. After 14 days of inoculation, mice were euthanized 
and liver, spleen, mesenteric lymph nodes (MLN) and cecum were harvested, 
homogenized and plated on XLD plates. Salmonella colonies were recovered from liver, 
spleen, MLN and cecum of live ST mice. Both EBST mice and sham mice did not 
recover viable Salmonella from organs. Absence of detectable viable Salmonella 
colonies confirmed that lethally irradiated ST at an eBeam dose of 7 kGy does not 
regrow in a susceptible mice model. The eBeam irradiated ST (EBST) cannot be re-
isolated from host and grown to pure culture and it is unable to cause any disease 
symptoms or mortality in susceptible host, thus rendering EBST to be non-pathogenic as 
per Koch’s postulate (Koch, 1876). Thus, eBeam irradiated ST at 7kGy (SD ±0.38) 
(EBST) could serve as a non-replicating vaccine candidate. 
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Table 4-2.  Inability of eBeam irradiated S. Typhimurium to multiply in vivo in a 
Salmonella susceptible mice model  
(A) Salmonella recovery from fecal pellets (FP) 
Days of FP 
collection 
Sham mice Live ST mice 
(Log CFU/g FP) 
EBST mice 
Day 3 BD* 4.79 ± 0.49 BD* 
Day 7 BD* 4.79 ± 0.23 BD* 
Day 10 BD* 4.61 ± 0.48 BD* 
Day 14 BD* 4.46 ± 0.51 BD* 
 
 (B) Salmonella recovery from organs 
Organ Sham mice Live ST mice 
(Log CFU/organ) 
EBST mice 
Liver BD# 2.24 ± 1.12 BD# 
Spleen BD# 2.07 ± 1.03 BD# 
Cecum BD# 4.73 ± 2.36 BD# 
MLN BDɸ 3.31 ± 1.65 BDɸ 
 
*, BD= Below detection limit of 1.69 log CFU 
#, BD= Below detection limit of 1.17 log CFU 
ɸ, BD= Below detection limit of 0.69 log CFU 
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EBST maintains an intact cell membrane 
To investigate whether eBeam irradiation causes damage to the bacterial cell 
membrane, the membrane integrity of EBST, HKST and live ST was assessed using the 
BacLight™ assay.  The BacLight™ assay utilizes the differential ability of two nucleic 
acid stains SYTO®9 and propidium iodide to penetrate healthy bacterial cells. SYTO®9 
can penetrate bacterial cells with either intact or damaged membrane staining them 
green. In contrast, propidium iodide can enter only the cells with a damaged membrane, 
causing reduction in SYTO®9 stain fluorescence when both dyes are present, thus 
staining the membrane damaged cells red. Hence, bacteria with intact membrane would 
stain fluorescent green, whereas bacteria with damaged cell membrane would stain 
fluorescent red. EBST maintained an intact cell membrane similar to live ST indicated 
by green fluorescent bacterial cells (Figure 4-2). Heat killed ST (HKST) stained red 
indicating loss of membrane integrity due to the heat treatment. This observation was 
further confirmed by ultra-structural examination of EBST using electron microscopy. 
EBST showed no discernable differences when examined by scanning electron 
microscopy compared to live ST controls (Figure 4-3). Increased morphological 
unevenness was observed in case of HKST as cell membrane appeared to be shrunken or 
caved in comparison to live and EBST. For detailed analysis, cross sections of bacteria 
were examined by Transmission Electron Microscopy (TEM). The EBST and live ST 
showed no significant difference (visually) in the cellular organization. Cell contents of 
HKST seemed to be disorganized and the cell membrane appeared to be detached from 
the periplasmic contents (Figure 4-4). Membrane damage can be clearly observed in case  
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Figure 4-2. Electron beam irradiated ST (EBST) maintains cell membrane integrity. 
Membrane integrity of S. Typhimurium remains unaffected by eBeam irradiation. 
Staining with Live/ Dead BacLight™ kit reveals the presence of intact cell membrane 
for (A) Live ST and (B) EBST indicated by the green labelled bacterial cells. Red 
colored staining of HKST (C) indicates disrupted cell membrane due to heat treatment. 
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Figure 4-3. Membrane morphology of EBST is similar to live ST. 
Scanning electron microscopic analysis shows presence of intact bacterial cell 
membrane for (A) Live ST and (B) EBST.  HKST (C) appears to be morphologically 
uneven with shrunken cell membrane. 
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Figure 4-4. Electron beam irradiation does not alter bacterial cellular organization in ST. 
Transmission electron micrographs of bacterial cross sections of (A) live ST and (B) 
EBST shows no alteration in the cellular organization. Heat treatment induces cellular 
disorganization and detachment of cell membrane from the periplasmic contents in 
HKST (C). 
 
  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. EBST retains cell surface molecules. 
Transmission electron micrographs of (A) live ST (B) EBST and (C) HKST reveals the 
presence of surface molecules on bacterial cell membrane of both live and EBST. HKST 
shows a smoothened surface indicative of loss of surface molecules  
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of HKST with the loss of surface structures. The cell membrane appears to be “smoothed 
out” and detached in comparison to the live and EBST (Figure 4-5). Membrane integrity 
assay together with electron microscopic studies provide evidence for the presence of an 
intact bacterial cell membrane in EBST which is structurally similar to live ST. 
EBST remains immotile but retains intact bacterial flagella 
Motility agar has been used in the past to verify bacterial motility (Hine et al., 
1988; Gomez et al., 1998). However, use of culture based motility agar was not 
applicable to EBST cells as they were non culturable in media. Hence, bacterial motility 
was assessed by observing wet mounts of bacterial cultures using phase contrast 
microscope. Care was taken to account for the motion due to Brownian movement. 
Brownian motion will allow bacterial cells to move along same direction in same speed, 
whereas truly motile bacteria would swim randomly or against the current across the 
slide.  EBST was found to be non motile in comparison to live ST. In order to check 
whether the reduction in motility was due to loss of flagella by eBeam irradiation, the 
bacterial flagella was examined by TEM using negative staining. Results from negative 
staining revealed that bacterial flagella were still attached and intact even after eBeam 
irradiation (Figure 4-6). 
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Figure 4-6. Electron beam irradiation preserves bacterial flagella in ST. 
Transmission electron micrographs (negative staining) of (A) Live ST and (B) EBST 
show presence of intact bacterial flagella.  
 
  
A 
B 
66 
 
Immunoreactivity profile of EBST proteins is similar to live ST 
To understand whether there is any loss of immunogenic Salmonella antigens in 
EBST preparation, immunoreactivity profile of EBST was developed and compared with 
live and heat killed ST. Using SDS PAGE, total soluble proteins from EBST, HKST and 
live ST were separated and immunoblotting was performed. Immune serum from mice, 
previously immunized with Salmonella was used as primary antibody to detect the 
Salmonella specific antigens in the respective bacterial preparation. The results showed 
that immunoreactivity profile of EBST was very similar to that of live ST which 
supports the absence of antigen loss in the EBST as a result of eBeam irradiation (Figure 
4-7). However, marked difference in the banding pattern was observed in case of HKST 
immunoreactivity profile in comparison to live and EBST, indicative of the loss of 
antigenic proteins due to heat treatment. Proteins extracted from EBST stored at 
different temperature conditions such as room temperature, 4°C, -20°C and lyophilized 
EBST were also analyzed to detect the Salmonella specific protein profiles. Storage at 
different temperature regimes did not induce any alteration in the immunoreactivity 
profiles of EBST. These findings suggests that immunoreactive proteins in EBST remain 
stable during storage at different temperature conditions. 
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Figure 4-7. EBST retains immunogenic proteins that are detected by live ST immune 
mice serum. 
After eBeam irradiation, ST was stored at multiple temperature conditions such as 4°C, -
20°C, and room temperature and as lyophilized preparation. Total soluble protein was 
extracted from all different EBST preparations. Proteins from live ST and heat 
inactivated ST were also extracted as controls. Proteins were separated using SDS-
PAGE and analyzed by western blotting. Immunodetction was carried out using 1/1000 
dilution of S. Typhimurium infected mice serum as the primary antibody and 1/ 20,000 
dilution of alkaline phosphatase conjugated sheep anti mouse IgG F(ab`)2 fragment as 
secondary antibody. EBST stored at room temperature (ER), 4°C (E4), -20°C (E20), 
lyophilized (ELy), Live ST (L), heat killed ST (HK), Protein ladder (M).  
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EBST retains metabolic activity 
Presence of enzymatic activity and cellular reducing conditions are considered as 
key indicators of metabolic activity of cells (Davey, 2011; Keer and Birch, 2003). In 
order to monitor the metabolic activity of S. Typhimurium post eBeam irradiation, the 
bacterial cells were subjected to Alamar blue® assay and biochemical assays 
(Rampersad, 2012). Fluorescence readings obtained from the Alamar Blue® assay 
indicate that EBST were metabolically active even after 10 days of storage at 4ºC 
(Figure 4-8).  The EBST cells exhibited higher metabolic activity compared to live ST. 
As expected, the heat inactivated ST had no residual metabolic activity. To avoid the 
possibility of erroneous detection of reduced compounds generated during the process of 
eBeam irradiation, metabolic activity of EBST cells followed by heat inactivation, and 
HKST followed by eBeam irradiation were measured. The EBST cells subjected to heat 
treatment before or after eBeam irradiation did not exhibit changes in fluorescence 
which confirmed that the increased fluorescence detected by Alamar Blue® is due to the 
reduced environment present in the metabolically active irradiated cells. 
The ability of bacteria to ferment specific carbohydrate in the media was tested 
by incubating EBST, HKST and live ST in Phenol Red Broth supplemented with 
sucrose. Media inoculated with EBST and live ST changed from red to yellow color 
whereas, no color change was observed in case of HKST (Figure 4-9A). The color 
change in media is due to acid production as a result of sugar fermentation by the 
bacteria. Despite the color change, EBST inoculated media lacked turbidity and gas  
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Figure 4-8. EBST remains metabolically active and retains the activity for extended time 
periods of storage at 4°C. 
Metabolic activity of S. Typhimurium post eBeam irradiation was measured using 
Alamar blue® assay. The reduced environment present in metabolically active cells were 
detected by redox indicator which fluoresces. The fluorescence readings obtained for 
EBST, live ST and heat killed ST (HKST) was measured on a daily basis up to 10 days 
and are reported as line graph. Metabolic activity of EBST cells followed by heat 
inactivation (EBST+HK) and HKST followed by eBeam irradiation (HKST+EB) were 
measured as process controls. 
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Figure 4-9. EBST remains metabolically active and tests positive for biochemical and 
enzymatic assays. 
(A) Carbohydrate utilization ability of EBST was tested by inoculating EBST into 
phenol red broth containing glucose and incubating for 48 h at 37°C. Live and heat 
killed S. Typhimurium were used as controls. Media color change, turbidity and gas 
production is monitored for all the samples. Arrow indicates gas production. (B) To 
assess the catalase enzymatic activity in EBST, cells were smeared on clean glass slide 
and a drop of 3% hydrogen peroxide was added. Bubble formation was monitored for 
detecting catalase activity. Live S. Typhimurium was used as a positive control. 
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formation that was present in live ST inoculated media. Thus, it was clear that EBST 
was not replicating in the media, but the inoculated cells were metabolically active to 
induce the fermentation and color change.  Presence of catalase enzyme in the irradiated 
cells was detected using catalase test. Catalase enzyme converts hydrogen peroxide to 
water and oxygen. The oxygen thus produced, forms bubbles which indicate the 
presence of intact catalase enzyme in the cells. Copious bubble formation was observed 
in both live and EBST cells (Figure 4-9B) which provided evidence for enzymatic 
activity in eBeam irradiated ST.  
EBST induces maturation of dendritic cells  
Dendritic cells (DC) are key antigen presenting cells (APC) which serve as 
functional junction between nonspecific innate immune response and antigen specific 
adaptive immune response mechanisms. Salmonella induces DC maturation, 
characterized by increased surface expression of MHC-II, co-stimulatory molecules and 
cytokine production (Pierre et al., 1997; Svensson et al., 2000). We tested the ability of 
EBST to trigger DC maturation in vitro using two murine DC models. The first model 
was a dendritic cell line DC2.4 (Shen et al., 1997) and second was a primary DC culture 
derived from bone marrow of C57BL/6J mice (BMDC) (Lutz et al., 1999). The DC2.4 
cells were stimulated with EBST, HKST and live S. Typhimurium for 24 h and the 
surface expression of MHC-II, CD40, CD80 (B7-1) and CD86 (B7-2) was analyzed. 
Production of proinflammatory cytokine TNFα was measured followed by 4 h of co-
incubation with stimulants. EBST induced efficient DC maturation indicated by the up-
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regulation of MHC-II, CD40, CD80 and CD86 surface expression on DC2.4 (Figure 4-
10). The level of DC maturation induced by EBST was similar to whole live ST and 
HKST. Increased production of TNFα by DC2.4 cells is indicative of the potent 
proinflammatory properties of EBST.  
The potential of stimulants (EBST, HKST and live ST) to induce DC maturation 
and activation over a range of concentration was assessed by  co-incubating stimulants 
and DC2.4 cells at a multiplicity of infection (MOI) of 100:1, 10:1, 1:1, 0.1:1, 0.01:1 
(Bacteria: DC). It was observed that expression levels of surface molecules and TNFα 
followed similar trend for EBST, HKST and live ST at higher MOI. A drop in 
expression level of CD40, CD80 and TNFα was noticed at MOI of 1 and below whereas, 
levels of MHC-II and CD86 remained consistent even at lower MOI (Figure 4-11A-E). 
At lower MOI, EBST and HKST induce similar expression levels of CD80 and TNFα 
which was significantly higher than live ST (Figure 4-11C, E). These results indicate 
that EBST possess agonist activity over a wide range of concentration. 
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Figure 4-10. EBST induces efficient DC maturation and triggers proinflammatory 
cytokine production in DC2.4 cells. 
DC2.4 cells were co-incubated with EBST, HKST and live S. Typhimurium (MOI 1:10 
for 24 h or 4 h) as indicated to the left side of each row of histograms. Each column of 
histogram represents expression level of surface markers MHC-II, CD40, CD80, CD86 
and proinflammatory cytokine TNFα. Percentages in the gated region indicate the 
proportion of DC expressing high levels of various surface markers and TNFα. 
Expression of levels of unstimulated DC (dotted red line) is compared to the antigen 
stimulated (thin black line) DC2.4 cells. Data are representative of three independent 
experiments. 
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Figure 4-11. EBST induces maturation of DC2.4 cells and retains the agonist activity 
over wide range of concentration. 
DC2.4 cells were coincubated with EBST, HKST and live S. Typhimurium at different 
multiplicity of infection (MOI) – 100, 10, 1, 0.1, 0.01, 0.001 for 24 h or 4 h. Line graphs 
represent the percentages of DC2.4 cells expressing high levels of (A) MHC-II, (B) 
CD40, (C) CD80, (D) CD86 and (E) TNFα.  Unstimulated controls were included to 
assess the basal level of expression of surface markers and proinflammatory cytokine by 
DC2.4 cells in the absence of any external stimulation.  
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Figure 4-11 Continued. 
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Earlier reports have shown that DC2.4 cell line exhibits relatively higher level of 
constitutive expression of MHC-I, MHC-II, CD80, CD86 and ICAM-1 (Alshamsan et 
al., 2010). Hence, DC maturation and activation ability of EBST was validated in vitro 
using primary DC culture derived from bone marrow of C57BL/6J mice (BMDC). For 
BMDC activation studies, EBST, HKST, live ST and a commercial live attenuated ST 
vaccine formulation (Salmune®, Ceva biomune, Lenexa, KS) were used as stimulants. 
Results from BMDC activation studies support the findings from DC2.4 cell line studies. 
When compared to the unstimulated media control, co-incubation of BMDC with 
stimulants generated a clear shift towards DC population expressing higher levels of 
MHC-II, CD40, CD80, CD86 and TNFα (Figure 4-12). Expression levels of surface 
markers and proinflammatory cytokine followed similar trend for stimulation with 
EBST, HKST, live ST and commercial ST vaccine. These results demonstrate that EBST 
without any adjuvant addition, possess similar potential to that of the commercial 
formulation, in inducing the DC maturation. Thus, EBST preserves the immunogenic 
properties enabling them to induce DC maturation. 
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Figure 4-12. EBST induces efficient DC maturation and triggers proinflammatory 
cytokine production in BMDC. 
BMDCs were coincubated with EBST, HKST, live S. Typhimurium and a commercially 
available live attenuated ST vaccine (MOI 1:10 for 24 h or 4 h) as indicated to the left 
side of each row of histograms. Each column of histogram represents expression level of 
surface markers MHC-II, CD40, CD80, CD86 and proinflammatory cytokine TNFα. 
Percentages in the gated region indicate the proportion of CD11c+ DC expressing high 
levels of various surface markers and TNFα. Expression of levels of unstimulated DC 
(dotted red line) is compared to the antigen stimulated (thin black line) DC. Data are 
representative of three independent experiments. 
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Figure 4-13. EBST induces maturation of BMDC and retains the agonist activity over 
wide range of concentration. 
BMDC were co-incubated with EBST, HKST, live S. Typhimurium and a commercially 
available ST vaccine at different multiplicity of infection (MOI) – 100, 10, 1, 0.1, 0.01 
for 24 h or 4 h. Line graphs represent the percentages of CD11c+ DC expressing high 
levels of (A) MHC-II, (B) CD40, (C) CD80, (D) CD86 and (E) TNFα.  Unstimulated 
controls (No Ag) were included to assess the basal level of expression of surface 
markers and proinflammatory cytokine by BMDC in the absence of any external 
stimulation. 
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Figure 4-13 Continued. 
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Figure 4-13 Continued.  
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Similar to the studies conducted in DC2.4 cells, BMDCs were also co-incubated 
with stimulants at multiple MOI, to investigate the influence of antigen concentration in 
inducing the DC maturation and activation. For this, DCs were infected with stimulants 
at different MOIs (100, 10, 1, 0,1, 0.01), and then cell surface expression of CD40, 
CD80, CD86 and MHC-II molecules was analyzed by flow cytometry at 24 h post 
stimulation, and proinflammatory cytokine TNFα production was measured after 4 h of 
co-incubation. A gradual reduction in the expression levels of surface markers were 
observed with decreasing MOI (Figure 4-13A-D). However, co-incubation of BMDC 
with stimulants at a high MOI of 100 impaired their ability to up-regulate co-stimulatory 
molecules and proinflammatory cytokine. It was found that MOI of 10 and 1 were most 
effective in inducing DC maturation for all the stimulants that were tested. Retention of 
agonist activity and TNFα production were low at lower MOI for EBST and live ST. 
Vaccination with EBST reduces virulent Salmonella colonization similar to live 
attenuated ST vaccine 
Live attenuated ST vaccines are known to be effective in inducing protection 
against virulent ST challenge (Harrison et al., 1997; Hormaeche et al., 1991; Mastroeni 
et al., 1992).  Therefore, the effect of EBST immunization was tested in comparison with 
AroA- ST, a widely studied live attenuated ST vaccine in mice model system (Harrison 
et al., 1997; Hormaeche et al., 1991; Killar and Eisenstein, 1985). Salmonella 
susceptible C57BL/6J mice were immunized with 2x 109 EBST and AroA- ST on day 0 
by oral gavage. Two booster doses were given to EBST immunized mice, with 2 x 109 
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EBST on day 14 and 28. A Sham immune control group of mice was maintained, which 
received PBS. After 14 weeks of primary vaccination, EBST immune, AroA immune 
and Sham immune mice were challenged orally with 1 x 108 virulent Nalidixic acid 
resistant Salmonella Typhimurium. Survivors in all three groups of mice were monitored 
up to day 7 post challenge. It was observed that, 70% of the EBST immune mice 
survived the virulent ST challenge (Figure 4-14).  AroA immune mice had relatively 
higher proportion i.e., 80% of survivors, when compared to only 60% survivors in case 
of sham immune mice. Mice were sacrificed 3 and 7 days post challenge, for assessing 
the bacterial bioburden on liver, spleen, mesenteric lymph nodes and cecum. A delayed 
onset of bacterial colonization was observed in case of AroA immune mice compared to 
EBST and sham immune mice (Figure 4-15 A, B).  On day 7, an increase in organ 
colonization was observed in all three mice groups. But, Sham immune mice had 
significantly higher bacterial CFU counts compared to EBST and AroA immune mice in 
liver and cecum (Figure 4-15 A, D). The difference in organ colonization between EBST 
and AroA immune mice were found to be statistically non-significant (p ≥ 0.05) 
indicating their similarity in controlling in vivo replication of bacteria. Overall, a 
relatively higher bacterial bio-burden was observed in all mice groups (Figure 4-15 A- 
D) which can be attributed to the high challenge titer of virulent ST. 
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Figure 4-14. Survival of EBST immune, AroA ST immune and sham immune mice till 7 
days post challenge with virulent S. Typhimurium. 
C57BL/6 mice were unimmunized (Sham) or immunized with 2x109 EBST, AroA ST on 
day 0 via oral gavage. EBST immune group was given two booster doses of 2x 109 
EBST on week 2 and 4. All mice groups were orally challenged with 1x 108 virulent S. 
Typhimurium and observed for survival till day 7 post challenge. Data shown is a 
censored Kaplan Meier survival curve for Sham immune (n=10), EBST immune (n=15), 
AroA immune (n=15)  
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Figure 4-15. Bacterial bioburden on organs of EBST, AroA and sham immune mice. 
EBST immune, AroA immune and sham immune mice were challenged with virulent 
ST, 14 weeks after primary vaccination. After 3 (n=5mice/group) and 7 (n=3-4 
mice/group) days of challenge mice were sacrificed and organ bacterial burden in (A) 
liver (B) spleen (C) mesenteric lymph nodes (MLN) and (D) cecum were determined. X 
axis represents log values of CFU/organ; bar denotes median values of log CFU for each 
group of mice; dotted line represents the limit of detection (Liver, spleen, cecum = 1.17 
log CFU; MLN = 0.69 log CFU). Kruskal wallis non parametric ANOVA was used for 
statistical analysis. *, median significantly different at p ≤ 0.05. 
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Figure 4-15 Continued. 
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EBST induces antigen specific cellular immune responses 
Live attenuated ST vaccines are supposedly more effective than inactivated 
vaccines in mice models, due to their ability to induce strong cell-mediated immunity 
(Collins, 1974; Harrison et al., 1997; Hormaeche et al., 1991; Mastroeni et al., 1992). 
Therefore, the ability of EBST immunized mice to develop antigen specific cellular 
immune response during virulent Salmonella challenge was tested. Mice were orally 
immunized with EBST, AroA ST and PBS (Sham immune). EBST immune mice were 
boosted twice at 2 weeks intervals via same route. All groups of mice were challenged 
with virulent ST, 14 weeks after primary immunization and spleens were harvested at 
days 3 and 7 post challenge. Frequencies of CD4+ and CD8+ T cells that produced 
cytokines IFNγ and TNF were measured after ex vivo re-stimulation of splenocytes with 
antigens for 24 h. Electron beam irradiated Salmonella (EBST) and heat killed 
Salmonella (HKST) were used as Salmonella specific antigens, whereas anti-CD3 
antibody was used as positive control for T cell stimulation.   
Measuring the frequency of IFNγ producing T cells provides a direct indication 
of the Th1 mediated immune response (Alaniz et al., 2007). In case of naïve and sham 
immune mice, frequencies of CD4+ T cell producing IFNγ or TNF spontaneously or in 
response to antigen stimulation, were found to be low on day 3 and day 7 post challenge 
(Figure 4-16, 4-17). However on day 7 post challenge, both EBST and AroA immune 
mice showed increased frequencies of CD4+IFNγ+ and CD4+TNF+ T cells that responded 
to antigens - EBST and HKST (Figure 4-18, 4-19).   
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Figure 4-16. Salmonella specific T cell (CD4+IFNγ+) responses by EBST immune mice during virulent ST challenge. 
Production of Th1 cytokine IFNγ by antigen specific CD4+ T cells was measured using intracellular cytokine staining (ICS) 
from individual EBST immune, AroA immune and Sham immune mice splenocytes at 3 and 7 days post infection with 
virulent ST. For comparison, naïve mice splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) 
and anti-CD3 (CD3) antibody as positive control. Unstimulated splenocytes were included as control. Percentages in the gated 
region indicate the proportion of CD4+IFNγ+ of total CD4+ splenocytes. Data are representative of three-five individual mice 
per group. 
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Figure 4-17. Salmonella specific T cell (CD4+ TNF+) responses by EBST immune mice during virulent ST challenge 
Production of cytokine TNF by antigen specific CD4+ T cells was measured using intracellular cytokine staining (ICS) from 
individual EBST immune, AroA immune and Sham immune mice splenocytes at 3 and 7 days post infection with virulent ST. 
For comparison, naïve mice splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) and anti-
CD3 antibody as positive control. Unstimulated splenocytes were included as control. Percentages in the gated region indicate 
the proportion of CD4+TNF+ of total CD4+ splenocytes. Data are representative of three-five individual mice per group. 
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Figure 4-18. EBST immune mice exhibit strong Salmonella specific CD4+IFNγ+T cell 
responses during virulent ST challenge. 
Production of cytokine IFNγ by antigen specific CD4+ T cells was measured using 
intracellular cytokine staining (ICS) from individual EBST immune, AroA immune and 
Sham immune mice splenocytes at (A) 3 and (B) 7 days post infection with virulent ST. 
Antigens used were EBST and HKST (2 x107 cells/ well) and anti-CD3 antibody as 
positive control. Unstimulated splenocytes were included as control. Data are 
represented as mean ± SEM of 3-5 mice per group. Y axis represents percentage of 
CD4+IFNγ+ of total CD4+ splenocytes.   
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Figure 4-19. EBST immune mice exhibit strong Salmonella specific CD4+TNF+ T cell 
responses during virulent ST challenge. 
Production of cytokine TNF by antigen specific CD4+ T cells was measured using 
intracellular cytokine staining (ICS) from individual EBST immune, AroA immune and 
Sham immune mice splenocytes at (A) 3 and (B) 7 days post infection with virulent ST. 
Antigens used were EBST and HKST (2 x107 cells/ well) and anti-CD3 antibody as 
positive control. Unstimulated splenocytes were included as control. Data are 
represented as mean ± SEM of 3-5 mice per group. Y axis represents percentage of 
CD4+TNF+ of total CD4+ splenocytes. 
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Compared to sham immune mice, EBST immune mice splenocytes had 
significantly high frequency of Salmonella specific CD4+IFNγ+ (p = 0.016) and 
CD4+TNF+ (p= 0.0043) T cells.  Both AroA and EBST immune mice showed an 
increase in antigen specific CD4+IFNγ+ and CD4+TNF+ T cells from day 3 to day 7 post 
challenge. CD4+Tcells responding to positive control anti-CD3 antibody indicates the 
presence of previously primed memory T cells in EBST and AroA immune mice 
splenocytes, that rapidly responded to the CD3 stimulation to produce cytokines IFNγ 
and TNF.  
Production of IFNγ and TNF by CD8+T cells in response to Salmonella specific 
antigen re-stimulation was also investigated. Frequency of antigen specific CD8+ T cells 
producing IFNγ was far lower compared to CD4+ T cells (Figure 4-20, 4-22).  Antigen 
specific CD8+ IFNγ+T cells were higher in AroA immune mice splenocytes compared to 
EBST and sham immune mice (Figure 4-20, 4-22). CD8+TNF+ T cells were found to be 
present in similar proportion in sham immune, AroA immune and EBST immune mice 
(Figure 4-21, 4-23). These results demonstrate the involvement of CD4+T cells rather 
than CD8+ T cells, as key player in cell mediated immune response of EBST immunized 
mice, triggering the production of Th1 cytokine IFNγ.  
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Figure 4-20. Salmonella specific T cell (CD8+IFNγ+) responses by EBST immune mice during virulent ST challenge. 
Production of cytokine IFNγ by antigen specific CD8+ T cells was measured using intracellular cytokine staining (ICS) from 
individual EBST immune, AroA immune and Sham immune mice splenocytes at 3 and 7 days post infection with virulent ST. 
For comparison, naïve mice splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) and anti-
CD3 antibody as positive control. Unstimulated splenocytes were included as control. Percentages in the gated region indicate 
the proportion of CD8+IFNγ+ of total CD8+ splenocytes. Data are representative of three-five individual mice per group 
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Figure 4-21. Salmonella specific T cell (CD8+ TNF+) responses by EBST immune mice during virulent ST challenge. 
Production of cytokine TNF by antigen specific CD8+ T cells was measured using intracellular cytokine staining (ICS) from 
individual EBST immune, AroA immune and Sham immune mice splenocytes at 3 and 7 days post infection with virulent ST. 
For comparison, naïve mice splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) and anti-
CD3 antibody as positive control. Unstimulated splenocytes were included as control. Percentages in the gated region indicate 
the proportion of CD8+TNF+ of total CD8+ splenocytes. Data are representative of three-five individual mice per group 
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Figure 4-22. Salmonella specific CD8+IFNγ+ T cell responses.  
Production of cytokine IFNγ by antigen specific CD8+ T cells was measured using 
intracellular cytokine staining (ICS) from individual EBST immune, AroA immune and 
Sham immune mice splenocytes at (A) 3 and (B) 7 days post infection with virulent ST. 
Antigens used were EBST and HKST (2 x107 cells/ well) and anti-CD3 antibody as 
positive control. Unstimulated splenocytes were included as control. Data are 
represented as mean ± SEM of 3-5 mice per group. Y axis represents percentage of 
CD8+IFNγ+ of total CD8+ splenocytes. 
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Figure 4-23. Salmonella specific CD8+TNF+ T cell responses.  
Production of cytokine TNF by antigen specific CD8+ T cells was measured using 
intracellular cytokine staining (ICS) from individual EBST immune, AroA immune and 
Sham immune mice splenocytes at (A) 3 and (B) 7 days post infection with virulent ST. 
Antigens used were EBST and HKST (2 x107 cells/ well) and anti-CD3 antibody as 
positive control. Unstimulated splenocytes were included as control. Data are 
represented as mean ± SEM of 3-5 mice per group. Y axis represents percentage of 
CD8+TNF+ of total CD8+ splenocytes. 
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EBST vaccination induces generation of antigen specific multifunctional CD4+ T 
cells  
Presence of multifunctional Th1 cells which can simultaneously secrete multiple 
cytokines such as IFNγ, TNF and IL-2 are found to be better correlates of vaccine 
induced protection compared to single cytokine secreting T cells (Darrah et al., 2007).  
The presence of CD4+IFNγ+TNF+ T cells in splenocytes from EBST, AroA and sham 
immune mice after in vitro restimulation with Salmonella specific antigens was tested 
(Figure 4-24). It was observed that both EBST and AroA immune mice splenocytes had 
higher frequencies of CD4+IFNγ+TNF+ T cells that responded to total Salmonella 
antigens. Sham immune mice on the other hand, did not trigger stimulation of 
multifunctional T cells (Figure 4-24, 4-25). EBST immune mice had significantly higher 
(p= 0.003) frequency of multifunctional CD4+ T cells compared to sham immune mice. 
Multifunctional CD4+ T cells were less stimulated in response to anti-CD3 antibody 
control (Figure 4-24). Thus, it was evident that immunization with EBST vaccine 
triggers production of multifunctional CD4+ T cells simultaneously secreting cytokines 
IFNγ and TNF.   
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Figure 4-24. Salmonella specific multifunctional CD4+ T cell responses by EBST 
immune mice during virulent Salmonella challenge. 
Simultaneous production of cytokine IFNγ and TNF by antigen specific CD4+ T cells 
was measured using multiparameter flow cytometry by intracellular cytokine staining 
(ICS) from individual EBST immune, AroA immune and Sham immune mice 
splenocytes at 7 days post infection with virulent ST. For comparison, naïve mice 
splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) and 
anti-CD3 antibody as positive control. Unstimulated splenocytes were included as 
control. Percentages in the gated region indicate the proportion of CD4+IFNγ+TNF+ of 
total CD4+ splenocytes. Data are representative of three individual mice per group. 
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Figure 4-25. EBST immune mice exhibit strong Salmonella specific multifunctional 
CD4+ T cells during virulent Salmonella challenge. 
Simultaneous production of cytokine IFNγ and TNF by antigen specific CD4+ T cells 
was measured using multiparameter flow cytometry by intracellular cytokine staining 
(ICS) from individual EBST immune, AroA immune and Sham immune mice 
splenocytes at 7 days post infection with virulent ST. For comparison, naïve mice 
splenocytes were included. Antigens used were EBST and HKST (2 x107 cells/ well) 
and anti-CD3 antibody as positive control. Unstimulated splenocytes were included as 
control. . Data are represented as mean ± SEM of 3 mice per group. Y axis represents 
percentage of CD4+IFNγ+TNF+ of total CD4+ splenocytes. 
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Induction of Salmonella specific IgG by EBST 
In order to check the levels of Salmonella specific IgG in the sera of EBST 
immunized mice indirect ELISA was performed. Mice were orally immunized with 
EBST, AroA ST and PBS (Sham immune). EBST immune mice were boosted twice at 2 
weeks intervals via same route. All groups of mice were challenged with virulent ST, 14 
weeks after primary immunization and serum was harvested from individual mouse on 
days 3 and 7 post challenge. Reactivity of mice sera to total Salmonella antigen – EBST, 
was tested using EBST coated ELISA plates. Results showed that both AroA and EBST 
immune mice had high serum IgG levels compared to sham immune mice (Figure 4-26). 
Although the serum IgG levels of EBST immune mice were lower than AroA immune 
mice (p = 0.0016), it was significantly higher compared to sham immune mice (p = 
0.0095). AroA immune mice had very high titers of serum IgG on both day 3 and day 7 
post-challenge which was significantly greater than sham immune mice (p ≤ 0.0005). 
Hence, it was observed that AroA immune mice developed strong Salmonella specific B 
cell response. Though the B cell response of EBST immune mice was slightly reduced, it 
was significantly greater than sham immune mice.  
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Figure 4-26. Mice immunized with EBST induced moderate Salmonella specifc IgG 
during virulent ST challenge. 
ELISA detection of Salmonella specific IgG in the sera of EBST immune, AroA 
immune and Sham immune mice were tested for reactivity to total Salmonella antigen 
(EBST) after 3 and 7 days after challenge with virulent S. Typhimurium. Serum from 
individual mice were diluted 1 in 500 and run in triplicates. Data are represented as 
mean ± SEM of 3 mice per group. Y axis represents S/P ratio (Sample OD450/ positive 
control OD450). Stastics analysis using Student’s unpaired t test was carried out to 
compare between groups. *, p ≤ 0.05; **, p ≤ 0.005; ***, p ≤ 0.0005. 
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EBST maintains immunogenic and proinflammatory properties during storage at 
room temperature for extended time period 
The ability of EBST vaccine to retain the immunogenic properties during storage 
at different temperature conditions was tested as a measure to assess the vaccine 
potency. Here, DC2.4 cell line was used as the in vitro model system to assess the DC 
maturation ability of EBST vaccine. EBST vaccines were stored up to 6 months at 4°C, -
20°C, and room temperature and as lyophilized preparations. These vaccines were 
analyzed on a monthly basis for their ability to activate DC. A freshly prepared live ST 
culture was also used to stimulate DC2.4 cells, which served as a positive control for DC 
maturation.  Expression of MHC-II and co-stimulatory molecules was measured using 
flow cytometry. The EBST vaccine preparation was found to be immunogenically stable 
evident by their consistent DC maturation capability up to 6 months of storage at various 
temperatures (Figure 4- 27A-D). Expression levels of DC maturation indicators such as 
CD40, MHC-II, CD80 and CD86 were up-regulated and were on par with the level of 
live ST stimulation (Figure 4- 27A-D). These findings provide evidence of EBST 
vaccine to be immunogenic when stored at room temperature for 6 months. Stability of 
EBST at room temperature for extended periods of time demonstrates the significant 
cost saving potential of such vaccines. 
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Figure 4-27. EBST remains immunogenically stable during storage at room temperature 
for extended time period. 
EBST vaccine stored at different temperature conditions such as room temperature (RT), 
4°C, -20°C and after lyophilization induced stable maturation of DC2.4 cells indicated 
by the upregulation of (A) MHC-II (B) CD40 (C) CD80 and (D) CD86 for up to 6 
months of storage. Freshly prepared live S. Typhimurium was included as a positive 
control to stimulate DC2.4 cells, unstimulated DC2.4 cell provided base level expression 
of different surface markers on DC2.4 cells. Data represents mean values of proportion 
of cells positive for indicated surface marker. 
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Figure 4-27. Continued. 
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CHAPTER V 
DISCUSSION 
 
The general rule behind vaccine development is - the more similar a vaccine is to 
the disease causing form of the organism, the better the immune response to the vaccine 
(CDC, 2012). This formed the basis for developing newer vaccine platforms that 
combine better immune response of live attenuated vaccines and safety profile of 
inactivated vaccines. The current study involves the use of electron beam (eBeam), as a 
next generation vaccine platform. Microbiological and immunological characterization 
of eBeam based vaccine against a model organism - Salmonella Typhimurium, was 
carried out. The eBeam S. Typhimurium (EBST) vaccine was developed by inactivating 
live S. Typhimurium (ST) using high energy electron beam. Bacterial inactivation by 
ionizing radiation occurs primarily due to direct/ indirect DNA damage (Ginoza, 1967; 
Sparrow et al., 1967), whereas damage to proteins or lipids contribute only minimally to 
the bacterial lethality (Kim and Thayer, 1995; Miller, 2005; Tahergorabi et al., 2012).  
The choice of an optimal eBeam dose for vaccine generation involves 2 major 
considerations: (1) should be high enough to ensure complete bacterial inactivation that 
prevents the ability of bacteria to repair the radiation induced damages and (2) should be 
low enough to preserve the integrity of immunological epitopes present on bacteria. 
Based on the inactivation kinetics analysis, D10 value of S. Typhimurium in PBS was 
calculated as 0.19 kGy, which is in agreement with previous studies reporting a D10 
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value of 0.2 kGy for S. Typhimurium in phosphate buffer (Thornley et al., 1963; Hansen 
and Shaffer, 2001). The ability of microorganism either to reproduce significantly in 
nutrient broth or to produce a colony forming unit on a recovery medium after exposure 
to radiation were monitored as parameters for microbial survival (Hansen and Shaffer, 
2001). Results from the recovery studies showed that S. Typhimurium completely losses 
its ability to multiply in TSB after subjecting to an eBeam dose of 7 kGy (Table 4-1). In 
vivo studies using Salmonella susceptible mice confirmed the inability of eBeam 
irradiated S. Typhimurium to multiply inside host system (Table 4-2).  The eBeam 
irradiated S. Typhimurium (EBST) cannot be re-isolated from the host and grown to 
pure culture. It is also unable to cause any disease symptoms or mortality in susceptible 
host, thus rendering EBST to be non-pathogenic as per Koch’s postulate (Koch, 1876). 
Based on the results from the bacterial inactivation studies and regrowth assays, EBST 
vaccine was generated by irradiating ~ 1x109 CFU/ml of ST at 7 (SD ±0.38) kGy (Figure 
4-1).   
Membrane integrity analysis using Baclight assay and electron microscopy 
revealed that EBST maintained an intact cell membrane similar to non -irradiated live 
ST (Figure 4-2, Figure 4-3). Ultrastructural analysis using TEM showed the presence of 
similar cell surface structures in both live ST and EBST (Figure 4-5). Studies conducted 
by Moustafa et al. (2011) and Sanakkayala et al. (2005), support these findings as they 
detected the presence of intact cell membrane in gamma irradiated Brucella sp.  
Similarly, the study on gamma irradiated Toxoxplasma gondii showed that irradiated 
cells had same morphology as non-irradiated cells with no evidence of clumped 
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chromatin or cytoplasmic damage (Hiramoto et al., 2002). In contrast to eBeam 
irradiation, cell membrane damage was clearly observed in ST subjected to heat 
inactivation. The difference between live ST, EBST and HKST was investigated 
immunologically by generating an immunoreactivity profile of Salmonella specific 
antigens in respective bacterial preparations using immune serum from mice previously 
immunized with live Salmonella (Figure 4-7). Results showed that HKST lacked several 
antigenic proteins, whereas EBST had a very similar immunoreactivity profile as live 
ST. Thus, it can be inferred that eBeam irradiation of S. Typhimurium at a dose of 7 kGy 
preserved the integrity of immunological epitopes present on bacteria. 
Although eBeam irradiation abrogated the reproductive ability of S. 
Typhimurium, EBST remained metabolically active, as shown by the results of Alamar 
blue assays and the biochemical assays (Figures 4-8 and 4-9). In the Alamar blue assay, 
increased fluorescence due to reduction of redox indicator resazurin to resorufin was 
observed in case of EBST and live ST cells. This indicates the presence of reduced 
environment in the irradiated cells that signifies the maintenance of metabolic activity by 
EBST. Positive results for the catalase assay indicates the presence of an intact catalase 
enzyme in the irradiated cell. The EBST was also found to be capable of fermenting 
sugar to produce acid, which requires coordinated action of multiple enzymes in the 
carbohydrate fermentation pathway. Detection of such enzymatic activities indicates that 
eBeam irradiation did not degrade enzymes present in the bacteria.  These findings are 
comparable to the previous reports of maintenance of metabolic activity by gamma 
irradiated Brucella sp. (Magnani et al., 2009; Moustafa et al., 2011; Sanakkayala et al., 
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2005) and Toxoplasma gondii (Hiramoto et al ., 2002).  As per the studies by Hiramoto 
et al. (2002) and Magnani et al. (2009), irradiation does not cause significant 
interference to cellular functions. They utilized various assays such mitochondrial 
respiratory assay, luminescent promoter assay, 3H-proline and 3H-hypoxanthine 
incorporation assays, to prove that gamma irradiated cells maintained oxidative function 
and preserved the ability for protein and nucleic acid synthesis. Studies have shown that, 
despite impairing microbial replication by DNA fragmentation, ionizing radiation leaves 
considerable portions of genome amplifiable in the irradiated cells (Trampuz et al., 
2006; Magnani et al., 2009). Thus, irradiated cells remain metabolically active and 
replication incompetent (Trampuz et al., 2006). The results from Alamar blue assay 
show that EBST retained metabolic activity for more than 10 days, with almost 2 fold 
increased activity over live ST (Figure 4-8). The increased activity might probably be 
due to DNA repair mechanisms.  Although increased metabolic activity have been 
previously reported in gamma irradiated Toxoplasma gondii (Hiramoto et al., 2002), the 
exact reason has not yet been studied conclusively. Based on the results from metabolic 
activity and biochemical assay and also considering the similarity with previous studies 
on gamma irradiated cells (Magnani et al., 2009; Moustafa et al., 2011; Sanakkayala et 
al., 2005; Hiramoto et al., 2002), we can infer that eBeam irradiation rendered S. 
Typhimurium metabolically active yet non culturable (MAyNC). Further studies are 
required to investigate the ability of EBST for de novo protein synthesis. 
Motility is considered as an important property of bacterial cells  that helps in 
obtaining nutrients from the environment and to survive in detrimental physicochemical 
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conditions (Martinez- Garcia et al., 2014). Flagella dependent motions help the bacterial 
cells to swim in liquid media and swarm on wet surfaces. Bacterial flagella also helps in 
adhesion, biofilm formation, and host invasion (Kirov et al., 2003). But, the role of 
bacterial motility in in vivo colonization is still unsettled as there were many conflicting 
reports on the requirement of flagella for virulence (Olsen et al., 2013; Lockman and 
Curtiss, 1990; Carsiotis et al., 1984; La Ragione et al., 2003). Bacterial motility 
assessment showed that EBST lacked motility. However, the lack of motility cannot be 
attributed to the detachment of flagella during eBeam irradiation, as it was observed 
using TEM that EBST preserved intact flagella (Figure 4-6). Several reports suggest that 
lack of bacterial motility occurs in bacteria undergoing stress, for the purpose of 
metabolic trade-off (Martnez-Garcia et al., 2014; Lu et al., 2013). The lack of flagellar 
motility might confer surplus energy (ATP) and reducing power (NADPH), that could be 
allocated to other cellular functions, which will help the bacteria to cope up with the 
stress better than wild type bacteria (Martinez- Garcia et al., 2014). These reports 
provide clues for the ability of EBST to be increasingly metabolically active in spite of 
being non-motile. Presence of intact flagella in EBST is important, as the flagella is 
considered as a key pathogen associated molecular pattern (PAMP) capable of triggering 
host immune response (Kawai and Akira, 2011; Olsen et al., 2013). 
In order to initiate a specific immune response against bacterial pathogens, 
bacterial antigens need to be captured, processed, and presented by specialized cells 
called antigen presenting cells (APC) (Banchereau and Steinman, 1998; Steinman, 
1991). The phagocytic cells such as macrophages and dendritic cells are the most widely 
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studied APC (Svensson et al., 2000; Yrlid et al., 2000). Even though, both macrophage 
and dendritic cell (DC) share many functional similarities, DC is considered more potent 
APC, capable of stimulating naïve T cells to initiate Salmonella specific immune 
response (Svensson et al., 2000; Yrlid et al., 2000). The ability of DC to interact with 
naïve T cells following antigen uptake, determines the specificity and polarization of the 
T cell mediated immunity (Surendran et al., 2010; Yrlid et al., 2001). Hence, the DC 
maturation potential of EBST was studied as the first step of immunological 
characterization. When encountered with appropriate inflammatory stimuli, immature 
DC undergoes process of maturation to develop as a fully competent APC (Sundquist et 
al., 2004; Yrlid et al., 2000). A mature DC is characterized by increased and stable 
surface expression of MHC molecules, upregulation of co-stimulatory molecule surface 
expression, as well as enhanced cytokine secretion (Pierre et al., 1997; Svensson et al., 
2000; Winzler et al., 1997). The results from in vitro DC stimulation assays using DC2.4 
cell line and BMDC showed that EBST provided optimal DC maturation and activation 
(Figures 4-10, 4-12). Upregulation of MHC-II, CD40, CD80, CD86 and TNFα 
production by DC was observed, when stimulated with EBST (Figure 4-10, 4-12). 
Interestingly, the level of expression of surface markers and cytokine secretion induced 
by EBST were on par with that induced by viable live ST. These results are consistent 
with previous studies conducted using gamma irradiated Brucella sp. and Listeria 
monocytogenes, which showed similar DC activation by irradiated, heat killed and live 
bacterial preparations (Sanakkayala et al., 2005; Datta et al., 2006). Conflicting reports 
have been published in the past with respect to the requirement of bacterial viability and 
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longer incubation time for DC maturation by Salmonella (Yrlid et al., 2001, Norimatsu 
et al., 2004; Svensson et al., 2000; Kalupahana et al., 2005). Studies by Yrlid et al. 
(2001) and Norimatsu et al. (2004) showed differential upregulation of CD40 and CD86 
surface molecules by live and heat killed Salmonella. By contrast, study by Svensson et 
al. (2000) showed no difference in expression levels of CD40, CD86 and MHC-II 
between live and heat killed Salmonella. Whereas, bacterial viability and internalization 
was found to be an important factor for CD80 expression levels. Findings by 
Kalupahana et al (2005) sheds light on the requirement of prolonged contact of DC with 
inactivated/ heat killed Salmonella to induce DC activation similar to live Salmonella. 
The findings by Kalupahana et al (2005) are in agreement with the present study as 
higher expression levels of MHC-II and co-stimulatory markers were observed after 24 h 
co-incubation with EBST and HKST (Figure 4-12). A commercial live attenuated ST 
vaccine was used as a control for BMDC maturation studies. For an appropriate 
comparison, DCs were stimulated with same MOI of EBST, HKST, live ST and 
commercial vaccine. The results suggested that EBST without any additional adjuvant, 
induced DC maturation similar to the commercial ST vaccine formulation (Figure 4-12). 
Besides activating DC, EBST also retained the agonist activity over wider antigen 
concentration (Figures 4-11, 4- 13). In conclusion, these findings demonstrate that, 
EBST can potently stimulate innate pro inflammatory response (TNFα) from DC, and 
can efficiently stimulate DC maturation (MHC-II, CD40, CD80 and CD86).   
Through the DC activation studies, it was observed that besides EBST and live 
ST, HKST served as an important inflammatory stimulus for triggering DC maturation 
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markers (Figures 4-10, 4- 12). But, unlike eBeam irradiation, heat inactivation resulted 
in disrupted cell membrane, altered cell surface morphology and disintegrated cellular 
contents in HKST (Figures 4-2, 4-3, 4-4, 4-5). HKST also suffered from loss of certain 
immunogenic Salmonella antigens (Figure 4-7), which remained intact in EBST and live 
ST. Together, these results suggest that EBST serves as a superior inflammatory 
stimulus to effect antigen specific immune response. 
Several studies have demonstrated higher level of protective immunity in mice 
by live Salmonella vaccines, compared to killed/ inactivated vaccines (Harrison et al., 
1997; Hormaeche et al., 1991; Killar and Eisenstein, 1985; Mastroeni et al., 1993; 
Lehmann et al., 2006; Thatte et al., 1993; Yrlid et al., 2001). Reports have shown that 
oral immunization with live attenuated AroA- ST vaccine generated Th1 type biased cell 
mediated immune response, hallmarked by the increased production of Th1 cytokine 
IFNγ (Killar and Eisenstein, 1985; Harrison et al., 1997; Lehman et al., 2006). Whereas, 
immunization with inactivated vaccines such as heat killed or purified bacterial 
components, generated an IL-4 dominated Th2- type response (Galdiero et al., 1998; 
Thatte et al., 1993). Therefore, the ability of EBST (metabolically active yet non 
culturable cells) to induce cellular immune response, in particular Th1 mediated immune 
response, was studied in comparison to a live attenuated Salmonella vaccine (AroA- ST). 
The ability of EBST vaccine to enable the host to rapidly produce Th1 derived cytokines 
- IFNγ and TNFα, in response to the virulent bacterial infection was monitored 
(Lehmann et al., 2006; Alaniz et al., 2007). The results showed activation of antigen 
specific IFNγ and TNF producing CD4+ T cells in both EBST immune and AroA 
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immune mice splenocytes (Figures 4-16).  Even though we observed activation of 
antigen specific CD4+TNF+ T cells in both EBST and AroA immune mice, the frequency 
of TNFα  producing cells were lower compared to IFNγ producing CD4+ T cells 
(Figures 4-17 and 19). TNFα production by CD4+ T cells in response to antigen 
stimulation occurs around 4 h of antigen co-incubation (Kalupahana et al., 2005). In the 
present study, intracellular cytokine staining was employed followed by multi-parameter 
flow cytometry to simultaneously analyze IFNγ+ and TNF+ T cells, in which BrefeldinA 
was added to plug Glogi bodies only after 18 h of co-incubation. So, the delay in 
addition of the Golgi plug™ might be responsible for the lower frequency of CD4+TNF+ 
T cells, as the cells might have already secreted considerable amount of TNF to the 
supernatant which was not detected with ICS. Interestingly, IFNγ and TNFα producing  
CD4+ T cells were also detected in un-stimulated EBST immune and AroA immune 
splenocytes, but not in case of sham immune mice(Figures 4-16 and 17).  Based on the 
bacterial colonization studies, it was observed that the spleens of EBST immune, AroA 
immune and sham immune mice were colonized heavily with challenge strain of 
Salmonella (Figure 4-15B). Hence, the un-stimulated splenocytes from EBST and AroA 
immune mice harbored challenge strain of Salmonella, which could have provided the 
trigger for secretion of IFNγ by CD4+ T cells. Even though, sham immune mice 
splenocytes also were colonized with Salmonella, very low frequencies of CD4+IFNg+ 
and CD4+TNF+T cells were found, which signifies the antigen specific immune response 
triggered by EBST and AroA immunization (Mastroeni et al., 2001; Dougan et al., 2011; 
Mastroeni and Menager, 2003).  
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Although we observed higher polyclonal stimulation of CD8+IFNγ+ T cells in 
both EBST and AroA immune mice, significant levels of antigen specific IFNγ 
producing CD8+ T cells were present only in case of AroA immune mice. In contrast to 
CD4+ T cells, CD8+ T cells are mostly restricted to MHC class-I molecules that present 
endogenous antigens processed by proteasome in cytosol of APC (Yrlid et al., 2000; 
Dougan et al., 2011). Consistent with the results of Yrlid et al. (2001), we observed that 
in AroA immunized mice; contribution of IFNγ production by Salmonella specific CD8+ 
T cells appeared to be minor compared to CD4+ T cells (Figure 4-20). Based on these 
findings, we can infer that EBST is capable of inducing Th1 type cellular immune 
response similar to live attenuated Salmonella vaccines. Therefore, unlike killed or 
inactivated vaccines (Thatte et al., 1993; Harrison et al., 1997), mice immunized with 
EBST develops robust Salmonella specific T cell response.  This result is similar to what 
was reported with gamma irradiation with Listeris sp. (Datta et al?) 
Although, production of IFNγ or effector cytokine TNF by CD4+ T cells is 
considered necessary to mediate protection, using it as a single immune parameter to 
predict protection may not be sufficient (Darrah et al., 2007). As IFNγ and TNF act 
synergistically to mediate pathogen control, use of multifunctional CD4+ T cells capable 
of simultaneously secreting IFNγ and TNF is considered a better correlate of protection 
(Darrah et al., 2007). Therefore, multi-parameter flow cytometry was used to assess the 
frequency of multifunctional CD4+ T cells simultaneously producing IFNγ and TNF 
(Figure 4-24). Increased Salmonella specific multifunctional CD4+IFNγ+TNF+ T cells 
were observed in EBST immune and AroA immunized mice (Figures 4-24 and 4-25). 
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Notably, nonspecific polyclonal stimulation of multifunctional CD4+ T cells were not 
observed in both EBST and AroA immune mice, which signifies the specificity of 
CD4+IFNγ+TNF+ T cells towards Salmonella antigens. EBST immune mice had 
significantly higher frequency of multifunctional CD4+ T cells compared to sham 
immune mice, but were relatively lower than AroA immune mice (Figure 4-25), which is 
consistent with the difference observed in bacterial colonization between the immunized 
mice groups (Figure 4-15).  
Preliminary survival analysis conducted on EBST, AroA and sham immune mice 
revealed no obvious deficiency in survival of EBST immune mice (Figure 4-14). But 
these results provide only an estimate of survival of immunized mice post virulent 
challenge, as large number of animals in the study was used for determining other 
correlates of protection. Future studies are needed with a larger  number of immunized 
mice dedicated for survival analysis. In order to determine the level of protective 
immunity in EBST, AroA and sham immune mice post virulent ST challenge, organ 
CFU was determined from liver, spleen, mesenteric lymph nodes and cecum. Results 
suggest that the extent of reduction of virulent Salmonella colonization in EBST immune 
mice were on par with that by AroA immune mice, whereas sham immune mice had 
high level of virulent Salmonella colonization (Figure 4-15). An increase in organ 
colonization was observed in EBST, AroA and sham immune mice from day 3 to day 7 
post challenge. Among all three groups of mice, sham immune mice exhibited 
substantial increase in level of organ colonization between day 3 and 7 post virulent ST 
challenge (Figure 4-15). The higher bacterial colonization observed in AroA immune 
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mice on day 7 post challenge might be because of the very high titer of (~ 2x 108 CFU) 
virulent Salmonella used for challenging the mice. EBST immune mice also had similar 
(not statistically significant) level of bacterial colonization as AroA immune mice. In 
future, more defined challenge studies need to be conducted with multiple vaccine dose 
regimes and challenge titers to definitively evaluate the protective immunity induced by 
EBST immune mice. 
The titers of Salmonella specific IgG antibody in AroA immune mice on day 3 
and day 7 post challenge, was found to be higher compared to EBST and sham immune 
mice.  Abundant antigen specific IgG indicates the development of strong Salmonella 
specific B cell response in AroA immune mice (Figure 4-26). Though the B cell 
response of EBST immune mice was slightly reduced, it was significantly greater than 
sham immune mice. These findings are consistent with previous studies which 
demonstrated the requirement of concerted action of cellular and humoral immune 
response to induce superior protection by live attenuated vaccine (Harrison et al., 1997; 
Thatte et al., 1993). Inactivated Salmonella vaccines such as heat killed ST have been 
shown to induce Salmonella specific IgG antibodies, when immunized via intra-
peritoneal or subcutaneous routes (Harrison et al., 1997; Thatte et al., 1993). Intra-
peritoneal administration of gamma irradiated Brucella elicited high titers of IgG, IgG1 
and IgG2a (Moustafa et al., 2011; Sanakkayala et al., 2005). Studies using eBeam 
irradiated S. Enteritidis intramuscularly administered to chicken, exhibited high 
Salmonella specific IgG after virulent Salmonella challenge (Jesudhasan et al., 2010). 
Results from these studies provides clue that EBST is capable of inducing B cell 
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response. But the IgG titer observed in the present study by the orally immunized EBST 
mice were lower compared to AroA immune mice, which could be improved by further 
optimization of immunization route and doses. 
Appropriate storage and handling of vaccines plays a key role in the success of 
immunization. Vaccines exposed to temperatures outside the recommended range can 
have reduced potency and protection (CDC, 2012). Hence it is important to maintain a 
proper cold chain, ie., temperature controlled supply chain for vaccine, which increases 
the cost of vaccination. The eBeam based vaccines may provide a rather inexpensive 
vaccine platform, especially with respect to storage and transportation without the 
requirement of cold chain. The ability of EBST vaccine to retain the immunogenic 
properties during storage at different temperature conditions was used as a measure to 
assess the vaccine potency. The vaccine potency of EBST over extended storage period 
was determined using in vitro DC2.4 activation model system. EBST retained stable 
immunogenic properties such as increased surface expression of DC maturation markers 
and production of proinflammatory cytokine, for several months at room temperature, 
4°C, -20°C and also after lyophilization (Figure 4-27).  These properties are considered 
to be of high value in any vaccine formulation (Ulmer et al., 2006). The EBST provided 
consistent and stable upregulation of DC maturation markers similar to live ST.  The 
EBST vaccine stability at room temperature or as lyophilized powder for extended 
storage period demonstrates immense cost saving potential of the vaccine. 
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Use of eBeam irradiation for vaccine production is a relatively novel field of 
research. Much work has been done by various research groups across the globe with 
regard to the development of gamma irradiated vaccines (Sanakkayala et al., 2005; Datta 
et al. 2006; Alsharifi and Mullbacher 2010; Furuya et al., 2010; Moustafa et al., 2011; 
Seder et al., 2013). Although the basic mechanism by which eBeam and gamma 
irradiation inactivate microorganisms is similar (Miller, 2005), there are fundamental 
differences between eBeam and gamma irradiation with respect to irradiation source, 
energy and dose-rate. Radioactive isotopes such as 137Cs and 60Co emit gamma radiation, 
whereas, electron beam is machine generated (linear accelerator), which does not 
involve any radioactive sources. The energy of gamma rays in 60Co is approximately 1 
MeV, while for high energy eBeam, it is around 10 MeV. The dose rate of gamma rays 
from 60Co is often in the range of hundreds of grays per minute, while in the case of 
eBeam the dose rate is in the range of tens of millions of grays per minute (Miller, 2005; 
Praveen et al., 2013). Thus, the high dose rate of high energy eBeam can compensate for 
the relatively limited penetration ability of eBeam. During eBeam irradiation, microbial 
pathogens experience ionizing radiation at significantly higher dose rate (usually in 
seconds) conditions compared to gamma irradiation, hence eBeam has a very short 
processing time compared to gamma. The eBeam is also ideal for integrating into a 
production line, hence suitable for commercial vaccine manufacturing. Additionally, 
eBeam technology serves as an environment friendly alternative to the radio nuclide 
based gamma irradiation. 
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Overall, it has been demonstrated that eBeam inactivation preserved the potent 
proinflammatory and immunogenic properties of S. Typhimurium. EBST remained 
metabolically active yet unable to multiply in vitro and in vivo. Increasing numbers of 
immunocompromised population who suffer from congenital immunodeficiency, 
immunosuppressive therapies, HIV patients are at risk of vaccine induced diseases after 
immunization with replicating vaccines (McFarland, 1999; Wolfe and Bhatt, 2005). 
Being a non-replicating vaccine, provides added advantage to eBeam based vaccines to 
be a potential immunization strategy for such immunocompromised individuals. 
Historically, non-replicating inactivated vaccines fail to induce adequate immune 
response, especially against pathogen requiring cell mediated immune response 
(Harrison et al., 1997; Robertsson et al., 1983; Thatte et al., 1993; Ulmer et al., 2006). 
But, metabolically active EBST induce substantial Salmonella specific T cell responses, 
thus playing a meaningful role in host response during infection. The eBeam based 
vaccine serves as a promising platform for commercial vaccine development as the 
immunogenic properties of EBST remained stable during storage at room temperature or 
after lyophilzation for extended time period. 
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CHAPTER VI 
SUMMARY 
 
1. The eBeam irradiation irreversibly inactivated S. Typhimurium. These cells were 
unable to multiply even under the most favorable in vitro and in vivo conditions. , 
Thus, eBeam irradiated S. Typhimurium has a better safety profile with reduced 
risk of reversion similar to killed/ inactivated vaccines. 
2. The eBeam irradiated S. Typhimurium maintained intact cell membrane, cell 
surface morphology and immunoreactivity profile similar to live ST. Thus it can 
be inferred that eBeam irradiated S. Typhimurium preserved the integrity of 
immunological epitopes present on bacteria. 
3. The eBeam irradiated S. Typhimurium maintained a reduced cellular 
environment similar to live bacterial cells, had functional enzymes and was 
capable of fermenting test carbohydrates. However, they were incompetent in 
terms of multiplication or in culture medium or a model animal host (mice). 
Thus, eBeam irradiated S. Typhimurium  remained metabolically active yet non 
culturable (MAyNC). 
4. The eBeam irradiated S. Typhimurium served as a superior inflammatory 
stimulus comparable to live ST or commercial vaccine - Salmune®. The eBeam 
irradiated S. Typhimurium  potently stimulated innate pro inflammatory response 
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by increased TNFα production from DC, and efficiently stimulated DC 
maturation by up-regulation of cell surface markers MHC-II, CD40, CD80 and 
CD86.   
5. In eBeam irradiated S. Typhimurium immunized mice, Salmonella specific 
CD4+T cells served as key player in cell mediated immune response, triggering 
the production of Th1 cytokine IFNγ. Increased Salmonella specific 
multifunctional CD4+IFNγ+TNF+ T cells simultaneously secreting IFNγ and TNF 
were observed in EBST immunized mice splenocytes. Therefore, it can be 
inferred that eBeam irradiated S. Typhimurium  is capable of inducing Th1 type 
cellular immune response similar to live attenuated Salmonella vaccines. 
6. The eBeam irradiated S. Typhimurium  immune mice were capable of reducing 
virulent Salmonella colonization in liver, spleen and cecum on par with that of 
AroA immune mice, whereas sham immune mice had higher levels of organ 
colonization. Hence, eBeam irradiated S. Typhimurium immunization can impart 
protective immunity to mice against virulent Salmonella challenge. 
7. The eBeam irradiated S. Typhimurium  retained stable immunogenic properties 
such as increased surface expression of DC maturation markers and production 
of proinflammatory cytokine, for up to 6 months at room temperature, 4°C, -
20°C and also after lyophilization. The wide range of temperature tolerance by 
eBeam irradiated S. Typhimurium indicates the significant cost saving potential 
of such vaccines by evading cold chain storage. 
121 
 
8. The eBeam based vaccine platform utilizes a green technology without the use of 
any chemicals and hence environmentally safe. The eBeam dose required for 
various level of inactivation can be delivered with high precision process control. 
The eBeam technology can also be customized to fit in to the vaccine 
manufacturing environment. Thus, eBeam technology serves as a promising next 
generation vaccine platform for commercial vaccine development. 
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